hydroxyproline has been researched along with Osteoporosis in 298 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 9.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| "To evaluate a therapeutic effect, biochemical parameters of bone metabolism and photonabsorption densitometry have been compared in patients with senile osteoporosis under long-term continuous or intermittent sodium fluoride treatment." | 9.04 | [Therapy of senile osteoporosis using sodium fluoride--continuous and intermittent long-term therapy]. ( Haber, P; Willvonseder, R, 1979) |
| "The aim of this study was to investigate the effect of evodiamine (EV) on dexamethasone-induced osteoporosis in zebrafish." | 7.91 | Preventive Effects of Evodiamine on Dexamethasone-Induced Osteoporosis in Zebrafish. ( Ma, Y; Su, Q; Wang, J; Wang, S; Wu, M; Yin, H, 2019) |
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 7.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| " pamidronate in patients with osteoporosis." | 7.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| "We have previously reported that long-term uninterrupted treatment of patients with osteoporosis with oral pamidronate is associated with increases in bone mineral content (BMC) of the lumbar spine which could not be explained by the antiresorptive action of the drug alone, raising the possibility of an additional effect of the treatment on skeletal tissue." | 7.69 | Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. ( Landman, JO; Papapoulos, SE, 1995) |
| "In 37 female patients with primary osteoporosis, urinary hydroxyproline excretion, determined in 18 24-h consecutive complete urine collections was compared with two radioisotopic measurements of bone resorption rate measured simultaneously using 85Sr." | 7.67 | Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. ( Deacon, AC; Green, JR; Hesp, R; Hulme, P; Reeve, J; Tellez, M, 1987) |
| "A significant correlation between the activity of the bone isoenzyme or serum alkaline phosphatase and the urinary hydroxyproline excretion in osteomalacia, osteoporosis, primary hyperparathyroidism with osteodystrophy, Paget's disease, secondary bone tumours, and in a control group was found (P less than 0." | 7.66 | Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. ( Formánková, J; Horn, V; Hrba, J; Konopásek, B; Marek, J; Pacovský, V; Silinková-Málková, E; Stĕpán, J; Vokrouhlická, O, 1978) |
| "the total hydroxyproline excretion in urine was investigated in 82 patients with hyperthyroidism without data fro a concomitant disease, 50 clinically healthy subjects with euthyroid struma, 10 patients with non endocrine froms of osteoporosis, 4 diabetics with not stable diabetic compensation and 4 patients with primary hyperparathyroidism." | 7.65 | [Urinary hydroxyproline in hyperthyroidism]. ( Baleva, R, 1977) |
| "Synthetic 1alpha-hydroxycholecalciferol, a potent vitamin D analogue, was given daily together with calcium to seven patients with senile osteoporosis and to three patients with prednisone-induced bone loss." | 7.65 | Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment. ( Andersen, RB; Friis, TH; Hjorth, L; Kjaer, I; Lund, B; Reimann, I; Sorensen, OH, 1977) |
| "daily for 4 weeks." | 5.28 | Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat. ( Gold, E; Goulding, A, 1990) |
| "Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease." | 5.27 | Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease. ( Bolzonella, S; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Paccagnella, A; Salvagno, L; Scalella, P, 1984) |
| "In women suffering from post-menopausal osteoporosis, we evaluated the effectiveness of two cyclic treatments with synthetic salmon calcitonin over a whole year, using an average daily dose of 16 and 32 IU, respectively." | 5.06 | Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity. ( Bertocchi, G; Gnudi, S; Mongiorgi, R; Moroni, A, 1988) |
| "The effects on calcium metabolism and forearm bone mineral density of sequential transdermal estradiol (ESTRADERM TTS-50), 50 micrograms/day and medroxyprogesterone (10 mg/day for 12 days) was studied in a randomised controlled trial in 34 healthy females 2-4 years after the menopause." | 5.06 | Transdermal estradiol in the treatment of postmenopausal bone loss. ( Adami, S; Bertoldo, F; Lo Cascio, V; Maresca, V; Residori, M; Rossini, M; Suppi, R, 1989) |
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 5.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| "There is increasing evidence that pamidronate and related compounds are effective in the prevention and treatment of osteoporosis." | 5.06 | Prevention of glucocorticoid-induced osteoporosis. ( Reid, IR; Schooler, BA; Stewart, AW, 1990) |
| "To evaluate a therapeutic effect, biochemical parameters of bone metabolism and photonabsorption densitometry have been compared in patients with senile osteoporosis under long-term continuous or intermittent sodium fluoride treatment." | 5.04 | [Therapy of senile osteoporosis using sodium fluoride--continuous and intermittent long-term therapy]. ( Haber, P; Willvonseder, R, 1979) |
| "The aim of this study was to investigate the effect of evodiamine (EV) on dexamethasone-induced osteoporosis in zebrafish." | 3.91 | Preventive Effects of Evodiamine on Dexamethasone-Induced Osteoporosis in Zebrafish. ( Ma, Y; Su, Q; Wang, J; Wang, S; Wu, M; Yin, H, 2019) |
| "In OVX rats, the increases of body weight, serum hydroxyproline (HOP) levels, and the decreases of uterus wet weight and BMD were significantly reversed by ECH treatment." | 3.79 | Antiosteoporotic activity of echinacoside in ovariectomized rats. ( Guo, C; Li, F; Li, P; Yang, X; Yang, Y; Yang, Z; Zhang, C, 2013) |
| "We studied the relation between common inexpensive markers of bone turnover (serum alkaline phosphatase (ALP), osteocalcin (OC), urinary hydroxyproline (OHPr), and calcium (Ca)), BMD, age, and menopause in a combined cross-sectional and longitudinal design comprising 429 pre- and postmenopausal randomly selected women aged 21-79 years (mean 50 years)." | 3.73 | Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. ( Larsson, L; Löfman, O; Magnusson, P; Toss, G, 2005) |
| "We investigated the effect of alendronate on calcium, PTH, and bone mineral density in 27 female and 5 male patients with primary hyperparathyroidism." | 3.71 | Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. ( Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR, 2002) |
| " pamidronate in patients with osteoporosis." | 3.71 | A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. ( Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002) |
| "We have previously reported that long-term uninterrupted treatment of patients with osteoporosis with oral pamidronate is associated with increases in bone mineral content (BMC) of the lumbar spine which could not be explained by the antiresorptive action of the drug alone, raising the possibility of an additional effect of the treatment on skeletal tissue." | 3.69 | Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. ( Landman, JO; Papapoulos, SE, 1995) |
| "Amine-carboxyboranes have been shown to prevent osteoporosis and loss of bone mass in rodents." | 3.69 | The anti-osteoporotic activity of amine-carboxyboranes in rodents. ( Chen, SY; Hall, IH; Rajendran, KG; Sood, A; Spielvogel, BF, 1995) |
| " An evaluation was made of deoxypyridinoline as well as other bone markets, such as alkaline phosphatase, tartrate resistant acid phosphatase, and hydroxyproline in patients with the diagnosis of osteoporosis." | 3.69 | [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies]. ( García Merlo, S; Grijalba Uche, A; Martínez Rodríguez, JL; Palacios Sarrasqueta, M; Rivero Marcotegui, A; Sorbet Zubiría, MJ, 1997) |
| "In 37 female patients with primary osteoporosis, urinary hydroxyproline excretion, determined in 18 24-h consecutive complete urine collections was compared with two radioisotopic measurements of bone resorption rate measured simultaneously using 85Sr." | 3.67 | Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. ( Deacon, AC; Green, JR; Hesp, R; Hulme, P; Reeve, J; Tellez, M, 1987) |
| "Serum calcium, albumin, phosphorus, and alkaline phosphatase, urinary creatinine and retention of 99mTc-methylene bisphosphonate (99mTc-MDP) were measured in 61 subjects with osteoporosis and the values compared with those obtained in normal subjects." | 3.67 | 99mTc-MDP retention in osteoporosis: relationship to other indices of bone cell activity and response to calcium and vitamin D therapy. ( Britton, JM; Davie, MW; Haddaway, M; McCall, IW, 1987) |
| "Twenty-one women with primary osteoporosis received an intramuscular injection of 100 IU of salmon calcitonin at 8 AM." | 3.67 | Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women. ( Ghiringhelli, G; González, D; Mautalen, C, 1986) |
| "We have measured classic markers of bone turnover, serum alkaline phosphatase (sAP), urinary hydroxyproline/creatinine ratio (uOH-Prol/creatinine) and osteocalcin (sBGP), in two bone disorders characterized by an increase in bone remodelling, namely Paget's disease of bone and primary hyperparathyroidism (PHPT) and in two other bone diseases characterized by an increase in bone resorption without the concomitant increase in bone formation, hypercalcaemia of malignancy (HM) and involutional osteoporosis (IO)." | 3.67 | Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis. ( de la Piedra, C; Rapado, A; Torres, R, 1989) |
| "We have studied some effects of small doses of 1,25-dihydroxycalciferol (calcitriol) and calcium, either combined or separately, in 45 patients with osteoporosis and malabsorption of calcium." | 3.67 | 1,25-Dihydroxycalciferol and calcium therapy in osteoporosis with calcium malabsorption. Dose response relationship of calcium absorption and indices of bone turnover. ( Horowitz, M; Need, AG; Nordin, BE; Philcox, JC, 1985) |
| "Free hydroxyproline was measured in plasma of 67 normal subjects and in 70 patients with bone disease including primary hyperparathyroidism (n = 19), osteoporosis (n = 18), Paget's disease (n = 14), cancer involving bone (n = 8), chronic renal failure (n = 6), and osteomalacia (n = 6), and osteomalacia (n = 5)." | 3.67 | Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease. ( Antonelli, R; Mazzuoli, G; Minisola, S, 1985) |
| "The osteoporosis which appears in paraplegics below the neurological lesion has been studied in 100 patients with the following parameters: quantitative X-rays, urinary hydroxyproline excretion, kinetic study of calcium metabolism by 45Ca, serum phosphorus and calcium, parathormone and calcitonin radio-immunoassay, quantitative histology, density fractionation of bone and amino-acid composition of fractionated bone analysis." | 3.66 | Actual concept of osteoporosis in paraplegia. ( Chantraine, A, 1978) |
| "Serum proline iminopeptidase and (where possible) urinary hydroxyproline were determined in 214 subjects: normal subjects, subjects with chronic kidney disease, subjects with chronic liver disease, subjects with osteitis deformans, subjects with rheumatoid arthritis, and subjects with osteoporosis." | 3.66 | [Rarefying osteopathy in rheumatology. Methods of evaluation and comparison of urinary hydroxyproline and serum proline iminopeptidase]. ( Carrozzo, M; D'Amore, M; Martiradonna, A; Quarto, S; Terlizzi, N, 1980) |
| "A significant correlation between the activity of the bone isoenzyme or serum alkaline phosphatase and the urinary hydroxyproline excretion in osteomalacia, osteoporosis, primary hyperparathyroidism with osteodystrophy, Paget's disease, secondary bone tumours, and in a control group was found (P less than 0." | 3.66 | Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. ( Formánková, J; Horn, V; Hrba, J; Konopásek, B; Marek, J; Pacovský, V; Silinková-Málková, E; Stĕpán, J; Vokrouhlická, O, 1978) |
| "the total hydroxyproline excretion in urine was investigated in 82 patients with hyperthyroidism without data fro a concomitant disease, 50 clinically healthy subjects with euthyroid struma, 10 patients with non endocrine froms of osteoporosis, 4 diabetics with not stable diabetic compensation and 4 patients with primary hyperparathyroidism." | 3.65 | [Urinary hydroxyproline in hyperthyroidism]. ( Baleva, R, 1977) |
| "Synthetic 1alpha-hydroxycholecalciferol, a potent vitamin D analogue, was given daily together with calcium to seven patients with senile osteoporosis and to three patients with prednisone-induced bone loss." | 3.65 | Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment. ( Andersen, RB; Friis, TH; Hjorth, L; Kjaer, I; Lund, B; Reimann, I; Sorensen, OH, 1977) |
| "Osteoclastic bone resorption, evaluated by urinary hydroxyproline excretion, was not stimulated in either group." | 2.67 | Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis. ( Bouillon, R; Dequeker, J; Devos, P; Geusens, P; Vanderschueren, D; Verstraeten, A, 1991) |
| "Significant increases in bone resorption markers were only seen at the end of the 28 d of injections, but were < 100% over baseline values, (P < 0." | 2.67 | An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. ( Adachi, JD; Fraher, LJ; Hodsman, AB; Ostbye, T; Steer, BM, 1993) |
| " At the dosage used (2." | 2.65 | Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. ( Hart, DM; Kraszewski, A; Lindsay, R, 1980) |
| " It is likely that a higher dosage would be more effective, but would cause the potential endometrial effects." | 2.65 | Bone loss during oestriol therapy in postmenopausal women. ( Clark, AC; Garwood, J; Hart, DM; Kraszewski, A; Lindsay, R; Maclean, A, 1979) |
| "Osteoporosis is the most common systemic skeletal disease characterized by low bone mass, increased bone turnover, and subsequent increased susceptibility to fracture." | 2.46 | [Osteoporosis--pathophysiology and laboratory diagnostic methods]. ( Blat, D; Komosińska-Vassev, K; Olczyk, K; Olczyk, P, 2010) |
| "Unique features of treatment for osteoporosis in Japan include rare use of estrogen replacement therapy, common use of vitamin D derivatives (especially 1alpha(OH) vitamin D) without notable side effects, and use of calcitonin almost exclusively in a low-dose intermittent regimen (20 U/week)." | 2.39 | Clinical guidelines for the treatment of osteoporosis in Japan. ( Fujita, T, 1996) |
| "The menopause is associated with a rise in obligatory urinary calcium loss resulting from an increase in the filtered load of calcium which may be due to the complexed fraction." | 2.37 | Calcium and osteoporosis. ( Horowitz, H; Morris, HA; Need, AG; Nordin, BE; Polley, KJ, 1988) |
| "Both alcohol and protein deficiency lead to reduced bone formation." | 1.33 | Effect of zinc supplementation on ethanol-mediated bone alterations. ( De la Vega-Prieto, MJ; Durán-Castellón, MC; García-Valdecasas Campelo, E; González-Reimers, E; López-Lirola, A; Martín-Olivera, R; Pérez-Ramírez, A; Santolaria-Fernández, F, 2005) |
| "Active hyperthyroidism is associated with reduced bone mass." | 1.30 | Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover. ( Escobar-Jiménez, F; Jódar Gimeno, E; Luna del Castillo, JD; Muñoz-Torres, M; Oleà, N; Quesada Charneco, M, 1997) |
| "Osteopenia was observed in nine patients (33%) and osteoporosis in another five (18%), according to the World Health Organization criteria." | 1.30 | Reduction of bone mass in women after bone marrow transplantation. ( Arranz, R; Carmona, L; Carvajal, I; Castañeda, S; Díaz, A; García-Vadillo, A, 1997) |
| "Osteoporosis was considered as a factor in spinal bone mineral density with a Z-score below 2 or at least one vertebral fracture." | 1.30 | Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. ( Guañabens, N; Martinez de Osaba, MJ; Monegal, A; Muñoz-Gómez, J; Navasa, M; Peris, P; Pons, F; Rimola, A; Rodés, J, 1997) |
| "All the urinary markers of bone resorption showed a prompt decline after bisphosphonates, with maximum reductions after 7-14 days: Pyr decreased by 43% +/- 9% and 42% +/- 22% (mean +/- SD), respectively in osteoporotic and pagetic subjects, OHP by 51% +/- 14% and 51% +/- 20%, and NTx by 55% +/- 15% and 65% +/- 26%." | 1.29 | Acute effects of bisphosphonates on new and traditional markers of bone resorption. ( Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M, 1995) |
| "The major mechanism of bone loss in myelomatosis is increased osteoclastic resorption but decreased bone formation contributes to bone loss with heavy plasma cell burdens." | 1.28 | Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. ( Beneton, MN; Greaves, M; Kanis, JA; McCloskey, EV; Rogers, S; Taube, T, 1992) |
| "We studied 22 patients with Klinefelter's syndrome (12 of whom had received sex hormone therapy) and 22 control subjects." | 1.28 | Osteoporosis and Klinefelter's syndrome. ( Horowitz, M; Morris, HA; Need, AG; Nordin, BE; O'Loughlin, PD; Wishart, JM, 1992) |
| "In conclusion, the further increase in bone resorption by thyroid hormone is predisposed by menopausal changes in bone turnover." | 1.28 | Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. ( Límanová, Z; Stĕpán, JJ, 1992) |
| "daily for 4 weeks." | 1.28 | Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat. ( Gold, E; Goulding, A, 1990) |
| "Bone resorption was monitored by measuring urinary hydroxyproline excretion." | 1.27 | Effects of NaCl on calcium balance, parathyroid function and hydroxyproline excretion in prednisolone-treated rats consuming low calcium diet. ( Goulding, A; McIntosh, J, 1986) |
| "Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease." | 1.27 | Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease. ( Bolzonella, S; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Paccagnella, A; Salvagno, L; Scalella, P, 1984) |
| "Osteoporosis is a common complication of corticosteroid therapy and it is associated with both decreased bone formation and increased bone resorption." | 1.27 | Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women. ( Hartley, TF; Need, AG; Nordin, BE; Philcox, JC, 1986) |
| "The prevalence of bone resorption relative to bone formation was evident even 12 years after oophorectomy, indicating continuous imbalance of bone remodeling in the patients." | 1.27 | Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. ( Pacovský, V; Pospíchal, J; Presl, J; Stĕpán, JJ, 1987) |
| "Finally, biochemical indices of bone resorption were high in osteoporotic patients and poorly correlated with histological bone resorption." | 1.27 | Bone turnover in spinal osteoporosis. ( Christiansen, C; Johansen, JS; Leth, A; Pødenphant, J; Riis, BJ; Thomsen, K, 1987) |
| "Ours results indicate an increase of bone resorption as a cause of postmenopausal osteoporosis." | 1.27 | Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause. ( Bordiu, E; Charro, A; Depablos, I; Espinos, D; Hernandez, ER; Rico, H, 1984) |
| "The long-term use of glucocorticoid drugs frequently results in the development of osteoporosis." | 1.27 | Calcium supplements in the prevention of steroid-induced osteoporosis. ( Ibbertson, HK; Reid, IR, 1986) |
| " Two dosage schedules were utilized for six months each: 2 units daily and 0." | 1.26 | Effects of growth hormone in osteoporosis. ( Aloia, JF; Cohn, SH; Ellis, K; Jowsey, J; Roginsky, M; Wallach, S; Zanzi, I, 1976) |
| "2." | 1.26 | The relation between bone loss and calcium balance in women. ( Crilly, RG; Horsman, A; Marshall, DH; Nordin, BE; Simpson, M, 1980) |
| "Before treatment, bone resorption was greater than normal in all but one patient and bone formation was normal." | 1.25 | Effect of sex hormones on bone in primary osteoporosis. ( Jones, JD; Jowsey, J; Kelly, PJ; Maher, FT; Riggs, BL, 1969) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 220 (73.83) | 18.7374 |
| 1990's | 51 (17.11) | 18.2507 |
| 2000's | 17 (5.70) | 29.6817 |
| 2010's | 9 (3.02) | 24.3611 |
| 2020's | 1 (0.34) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, Z | 1 |
| Xie, D | 1 |
| Huang, C | 1 |
| Ding, R | 1 |
| Zhang, R | 1 |
| Li, Q | 1 |
| Lin, C | 1 |
| Qiu, Y | 1 |
| Yin, H | 1 |
| Wang, J | 1 |
| Wu, M | 1 |
| Ma, Y | 1 |
| Wang, S | 1 |
| Su, Q | 1 |
| Pan, XY | 1 |
| Chen, CH | 1 |
| Chang, YH | 1 |
| Wang, DY | 1 |
| Lee, YC | 1 |
| Liou, CC | 1 |
| Wang, YX | 1 |
| Hu, CC | 1 |
| Kuo, TR | 1 |
| Li, F | 1 |
| Yang, X | 1 |
| Yang, Y | 1 |
| Guo, C | 1 |
| Zhang, C | 1 |
| Yang, Z | 1 |
| Li, P | 1 |
| Bezsmertnyĭ, IuO | 1 |
| Zhang, HS | 1 |
| Li, T | 1 |
| Liu, XS | 1 |
| Wang, FC | 1 |
| Yao, X | 1 |
| Yan, L | 1 |
| Liang, WJ | 1 |
| Kimira, Y | 1 |
| Mano, H | 1 |
| de Rougemont, A | 1 |
| Mourot, MG | 1 |
| Riou, JP | 1 |
| Trifonova, EB | 1 |
| Osipenko, AV | 1 |
| Guo, XX | 1 |
| Zhou, JL | 1 |
| Xu, Q | 1 |
| Lu, X | 1 |
| Liang, YJ | 1 |
| Weng, J | 1 |
| Shi, XL | 1 |
| Jeon, BJ | 1 |
| Ahn, J | 1 |
| Kwak, HS | 1 |
| Seferos, N | 1 |
| Kotsiou, A | 1 |
| Petsaros, S | 1 |
| Rallis, G | 1 |
| Tesseromatis, C | 1 |
| Komosińska-Vassev, K | 1 |
| Olczyk, P | 1 |
| Olczyk, K | 1 |
| Blat, D | 1 |
| Parker, CR | 1 |
| Blackwell, PJ | 1 |
| Fairbairn, KJ | 1 |
| Hosking, DJ | 2 |
| KLEIN, L | 3 |
| LAFFERTY, FW | 1 |
| PEARSON, OH | 1 |
| CURTISS, PH | 1 |
| DUBOVSKY, J | 3 |
| FORMANKOVA, J | 2 |
| DUBOVSKA, E | 1 |
| SMITH, DA | 3 |
| NORDIN, BE | 23 |
| SCRIVER, CR | 1 |
| GOLDBLOOM, RB | 1 |
| ROY, CC | 1 |
| MOSKOWITZ, RW | 1 |
| KATZ, D | 1 |
| JASANI, C | 2 |
| SWANSON, I | 1 |
| CRABBE, P | 1 |
| ISSELBACHER, KJ | 1 |
| Lello, S | 1 |
| Paoletti, AM | 1 |
| Migliaccio, S | 1 |
| Melis, GB | 1 |
| Löfman, O | 1 |
| Magnusson, P | 1 |
| Toss, G | 1 |
| Larsson, L | 1 |
| González-Reimers, E | 1 |
| Durán-Castellón, MC | 1 |
| Martín-Olivera, R | 1 |
| López-Lirola, A | 1 |
| Santolaria-Fernández, F | 1 |
| De la Vega-Prieto, MJ | 1 |
| Pérez-Ramírez, A | 1 |
| García-Valdecasas Campelo, E | 1 |
| Deyhim, F | 1 |
| Garica, K | 1 |
| Lopez, E | 1 |
| Gonzalez, J | 1 |
| Ino, S | 1 |
| Garcia, M | 1 |
| Patil, BS | 1 |
| Stĕpán, J | 4 |
| Brémová, A | 1 |
| Borel, JP | 1 |
| Caranjot, JM | 1 |
| Jayle, MF | 1 |
| Julkunen, H | 1 |
| Rokkanen, P | 1 |
| Jounela, A | 1 |
| Birkenhäger, JC | 1 |
| van der Heul, RO | 1 |
| Smeenk, D | 1 |
| van der Sluys Veer, J | 2 |
| van Seters, AP | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Krane, SM | 2 |
| Paterson, CR | 1 |
| Losowsky, MS | 1 |
| Brown, JP | 1 |
| Delmas, PD | 3 |
| Malaval, L | 1 |
| Edouard, C | 3 |
| Chapuy, MC | 1 |
| Meunier, PJ | 1 |
| Nuti, R | 1 |
| Righi, G | 1 |
| Turchetti, V | 1 |
| Vattimo, A | 2 |
| Gallagher, JC | 4 |
| Riggs, BL | 6 |
| DeLuca, HF | 1 |
| Christiansen, C | 4 |
| Rødbro, P | 2 |
| Tjellesen, L | 1 |
| Aloia, JF | 3 |
| Vaswani, AN | 1 |
| Yeh, JK | 1 |
| Ellis, K | 3 |
| Cohn, SH | 3 |
| Rico, H | 2 |
| Charro, A | 1 |
| Depablos, I | 1 |
| Bordiu, E | 1 |
| Hernandez, ER | 1 |
| Espinos, D | 1 |
| Gundberg, CM | 1 |
| Lian, JB | 1 |
| Gallop, PM | 1 |
| Steinberg, JJ | 2 |
| Horowitz, M | 8 |
| Need, AG | 10 |
| Philcox, JC | 4 |
| Bolzonella, S | 1 |
| Paccagnella, A | 1 |
| Salvagno, L | 1 |
| Chiarion Sileni, V | 1 |
| De Besi, P | 1 |
| Scalella, P | 1 |
| Fiorentino, MV | 1 |
| de Vernejoul, MC | 1 |
| Marie, P | 2 |
| Kuntz, D | 2 |
| Gueris, J | 1 |
| Miravet, L | 3 |
| Ryckewaert, A | 1 |
| Pilonchery, G | 1 |
| Minaire, P | 3 |
| Milan, JJ | 1 |
| Revol, A | 1 |
| Goulding, A | 3 |
| D'Amore, M | 2 |
| Quarto, S | 1 |
| Terlizzi, N | 1 |
| Martiradonna, A | 1 |
| Carrozzo, M | 2 |
| Lindsay, R | 5 |
| Hart, DM | 6 |
| Kraszewski, A | 3 |
| Heyburn, PJ | 1 |
| Peacock, M | 1 |
| Horsman, A | 6 |
| Aaron, J | 2 |
| Marshall, D | 1 |
| Crilly, RG | 4 |
| Hobitz, H | 1 |
| Rico Lenza, H | 4 |
| Burnell, JM | 1 |
| Baylink, DJ | 3 |
| Chestnut, CH | 1 |
| Mathews, MW | 1 |
| Teubner, EJ | 1 |
| Burckhardt, P | 3 |
| Rosa García, M | 1 |
| Paniagua Garrido, MC | 1 |
| del Río Vázguez, A | 1 |
| Huertas García-Alejo, R | 1 |
| Cohen, L | 1 |
| Kitzes, R | 1 |
| Schubert, L | 1 |
| Livello, ML | 1 |
| Belloni, M | 1 |
| Polvani, F | 1 |
| Naftchi, NE | 1 |
| Viau, AT | 1 |
| Sell, GH | 1 |
| Lowman, EW | 1 |
| Jones, MM | 1 |
| Marshall, DH | 6 |
| Simpson, M | 1 |
| Manicourt, DH | 1 |
| Orloff, S | 1 |
| Brauman, J | 1 |
| Schoutens, A | 1 |
| Plosker, GL | 1 |
| Goa, KL | 1 |
| Landman, JO | 1 |
| Papapoulos, SE | 2 |
| Rajendran, KG | 1 |
| Chen, SY | 1 |
| Sood, A | 1 |
| Spielvogel, BF | 1 |
| Hall, IH | 1 |
| Pedrazzoni, M | 1 |
| Alfano, FS | 1 |
| Gatti, C | 1 |
| Fantuzzi, M | 1 |
| Girasole, G | 1 |
| Campanini, C | 1 |
| Basini, G | 1 |
| Passeri, M | 4 |
| Wishart, JM | 2 |
| Morris, HA | 7 |
| Lorenc, R | 2 |
| Sims, NA | 1 |
| Moore, RJ | 1 |
| Durbridge, TC | 1 |
| Gonzalez-Calvín, JL | 1 |
| Garcia-Sanchez, A | 1 |
| Bellot, V | 1 |
| Muñoz-Torres, M | 2 |
| Raya-Alvarez, E | 1 |
| Salvatierra-Rios, D | 1 |
| Reeve, J | 2 |
| Loftus, J | 1 |
| Hesp, R | 2 |
| Ansell, BM | 1 |
| Wright, DJ | 1 |
| Woo, PM | 1 |
| Parto, K | 1 |
| Penttinen, R | 1 |
| Paronen, I | 1 |
| Pelliniemi, L | 1 |
| Simell, O | 1 |
| Hodsman, AB | 2 |
| Fraher, LJ | 2 |
| Ostbye, T | 1 |
| Adachi, JD | 1 |
| Steer, BM | 1 |
| Stĕpán, JJ | 3 |
| Schreiber, V | 1 |
| Schmidt-Gayk, H | 1 |
| Motoie, H | 1 |
| Kanoh, H | 1 |
| Ogata, S | 1 |
| Kawamuki, K | 1 |
| Shikama, H | 1 |
| Fujikura, T | 1 |
| Fujita, T | 3 |
| Vered, I | 1 |
| Kaiserman, I | 1 |
| Sela, BA | 1 |
| Sack, J | 1 |
| Monegal, A | 1 |
| Navasa, M | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Pons, F | 1 |
| Martinez de Osaba, MJ | 1 |
| Rimola, A | 1 |
| Rodés, J | 1 |
| Muñoz-Gómez, J | 1 |
| Maini, M | 1 |
| Brignoli, E | 1 |
| Felicetti, G | 1 |
| Bozzi, M | 1 |
| Castañeda, S | 1 |
| Carmona, L | 1 |
| Carvajal, I | 1 |
| Arranz, R | 1 |
| Díaz, A | 1 |
| García-Vadillo, A | 1 |
| Talbot, JR | 1 |
| Fischer, MM | 1 |
| Farley, SM | 1 |
| Libanati, C | 1 |
| Farley, J | 1 |
| Tabuenca, A | 1 |
| Eastell, R | 1 |
| Blumsohn, A | 1 |
| Rivero Marcotegui, A | 1 |
| Palacios Sarrasqueta, M | 1 |
| Grijalba Uche, A | 1 |
| Martínez Rodríguez, JL | 1 |
| Sorbet Zubiría, MJ | 1 |
| García Merlo, S | 1 |
| Jódar Gimeno, E | 1 |
| Escobar-Jiménez, F | 1 |
| Quesada Charneco, M | 1 |
| Luna del Castillo, JD | 1 |
| Oleà, N | 1 |
| Scopacasa, E | 1 |
| Ohishi, T | 1 |
| Takahashi, M | 1 |
| Kushida, K | 1 |
| Yamazaki, K | 1 |
| Hoshino, H | 1 |
| Kitazawa, A | 1 |
| Inoue, T | 1 |
| Titus, K | 1 |
| Baxter, BJ | 1 |
| Andrews, RN | 1 |
| Barrell, GK | 1 |
| Sahota, O | 1 |
| Masud, T | 1 |
| San, P | 1 |
| Schlemmer, CK | 1 |
| Coetzer, H | 1 |
| Claassen, N | 1 |
| Kruger, MC | 1 |
| Langdahl, BL | 1 |
| Løkke, E | 1 |
| Carstens, M | 1 |
| Stenkjaer, LL | 1 |
| Eriksen, EF | 1 |
| Chlebna-Sokół, D | 1 |
| Jakubowska, E | 1 |
| Sikora, A | 1 |
| Voskaridou, E | 1 |
| Kyrtsonis, MC | 1 |
| Terpos, E | 1 |
| Skordili, M | 1 |
| Theodoropoulos, I | 1 |
| Bergele, A | 1 |
| Diamanti, E | 1 |
| Kalovidouris, A | 1 |
| Loutradi, A | 1 |
| Loukopoulos, D | 1 |
| Henderson, K | 1 |
| Eisman, J | 1 |
| Keogh, A | 1 |
| MacDonald, P | 1 |
| Glanville, A | 1 |
| Spratt, P | 1 |
| Sambrook, P | 1 |
| Schmolke, B | 1 |
| Swaminathan, R | 2 |
| Husek, P | 1 |
| Pohlídal, A | 1 |
| Slabík, D | 1 |
| Cremers, S | 1 |
| Sparidans, R | 1 |
| den, HJ | 1 |
| Hamdy, N | 1 |
| Vermeij, P | 1 |
| Papapoulos, S | 1 |
| Nakatsuka, K | 1 |
| Nishizawa, Y | 1 |
| Lund, B | 2 |
| Hjorth, L | 2 |
| Kjaer, I | 2 |
| Reimann, I | 2 |
| Friis, T | 1 |
| Andersen, RB | 2 |
| Sorensen, OH | 2 |
| Aitken, JM | 1 |
| MacDonald, EB | 1 |
| Anderson, JB | 1 |
| Clarke, AC | 1 |
| Pacovský, V | 4 |
| Horn, V | 1 |
| Silinková-Málková, E | 2 |
| Vokrouhlická, O | 1 |
| Konopásek, B | 1 |
| Hrba, J | 1 |
| Marek, J | 1 |
| Haber, P | 1 |
| Willvonseder, R | 1 |
| Chantraine, A | 2 |
| Heynen, G | 1 |
| Franchimont, P | 2 |
| Dequeker, J | 4 |
| Lockwood, DR | 1 |
| Vogel, JM | 3 |
| Schneider, VS | 1 |
| Hulley, SB | 3 |
| Wiegmann, T | 1 |
| Kirsh, J | 1 |
| Rosenthall, L | 1 |
| Kaye, M | 1 |
| Kistler, H | 1 |
| Guha, P | 1 |
| Hanes, F | 1 |
| Oldfield, W | 1 |
| Purdie, D | 1 |
| Ferguson, MM | 1 |
| Clark, AS | 1 |
| Maclean, A | 1 |
| Garwood, J | 1 |
| Clark, AC | 1 |
| Verch, RL | 1 |
| Wallach, S | 3 |
| Peabody, RA | 1 |
| del Rio Vázquez, A | 1 |
| Vázquez Salamanica, E | 1 |
| Espinos Pérez, D | 2 |
| Claus-Walker, J | 1 |
| Carter, RE | 1 |
| Campos, RJ | 1 |
| Spencer, WA | 1 |
| Zanzi, I | 2 |
| Vaswani, A | 1 |
| Vigo, PL | 1 |
| Di Ciano, L | 1 |
| Girardello, R | 1 |
| Reschini, E | 1 |
| Polli, E | 1 |
| Lindholm, TS | 1 |
| Sevastikoglou, JA | 1 |
| Lindgren, U | 1 |
| Crilly, R | 1 |
| Cawood, M | 1 |
| Burssens, A | 1 |
| Creytens, G | 1 |
| Bouillon, R | 2 |
| Fournié, A | 1 |
| Valverde, C | 1 |
| Tap, G | 1 |
| Bazerque, JJ | 1 |
| Ayrolles, C | 1 |
| Friis, TH | 1 |
| Manzke, E | 1 |
| Rawley, R | 1 |
| Vose, G | 1 |
| Roginsky, M | 2 |
| Rader, JI | 1 |
| Baleva, R | 1 |
| Olah, AJ | 2 |
| Alexandrow, K | 1 |
| Dambacher, MA | 3 |
| Häfeli, W | 1 |
| Heer, KR | 1 |
| Lauffenburger, T | 1 |
| Haas, HG | 3 |
| Goldsmith, RS | 5 |
| Jowsey, J | 7 |
| Dubé, WJ | 1 |
| Arnaud, CD | 3 |
| Kelly, PJ | 3 |
| Laitinen, O | 1 |
| Kruse, HP | 3 |
| Kuhlencordt, F | 3 |
| Aaron, JE | 1 |
| Marcinowska-Suchowierska, E | 1 |
| Lisawa, A | 1 |
| Marowska, J | 1 |
| Lorencewicz, Z | 1 |
| Tałałaj, M | 1 |
| Brzozowski, R | 1 |
| Biondi, M | 1 |
| Costi, D | 1 |
| Bufalino, L | 1 |
| Castiglione, GN | 1 |
| Di Peppe, C | 1 |
| Abate, G | 1 |
| Taube, T | 1 |
| Beneton, MN | 1 |
| McCloskey, EV | 1 |
| Rogers, S | 1 |
| Greaves, M | 1 |
| Kanis, JA | 1 |
| Laitinen, K | 1 |
| Lamberg-Allardt, C | 1 |
| Tunninen, R | 1 |
| Härkönen, M | 1 |
| Välimäki, M | 1 |
| O'Loughlin, PD | 1 |
| Rohn, RD | 1 |
| Werner, EJ | 1 |
| Byrd, RL | 1 |
| Límanová, Z | 2 |
| Parfitt, AM | 2 |
| Preedy, VR | 1 |
| Baldwin, DR | 1 |
| Keating, JW | 1 |
| Salisbury, JR | 1 |
| Cornuz, J | 1 |
| Paccaud, F | 1 |
| Thiébaud, D | 1 |
| Geusens, P | 1 |
| Vanderschueren, D | 1 |
| Verstraeten, A | 1 |
| Devos, P | 1 |
| Rüegsegger, P | 1 |
| Mitsuma, T | 1 |
| Gold, E | 1 |
| Reid, IR | 3 |
| Schooler, BA | 1 |
| Stewart, AW | 1 |
| Lips, P | 1 |
| van Ginkel, FC | 1 |
| Netelenbos, JC | 1 |
| Wiersinga, A | 1 |
| van der Vijgh, WJ | 1 |
| Ferrández, L | 1 |
| Martín, M | 1 |
| Fernández, M | 1 |
| Woo, J | 1 |
| Lau, E | 1 |
| Pang, CP | 1 |
| MacDonald, D | 1 |
| Smith, ML | 1 |
| Fogelman, I | 1 |
| Scott, E | 1 |
| Bevan, J | 1 |
| Leggate, I | 2 |
| Gluckman, PD | 1 |
| Ibbertson, HK | 2 |
| Adami, S | 1 |
| Suppi, R | 1 |
| Bertoldo, F | 1 |
| Rossini, M | 1 |
| Residori, M | 1 |
| Maresca, V | 1 |
| Lo Cascio, V | 1 |
| Nishimoto, SK | 1 |
| Padilla, SM | 1 |
| Torres, R | 1 |
| de la Piedra, C | 1 |
| Rapado, A | 1 |
| Palummeri, E | 2 |
| Baroni, MC | 1 |
| Quaini, F | 1 |
| Quintavalla, A | 1 |
| Barbagallo, M | 1 |
| Franchini, D | 1 |
| Ugolotti, D | 1 |
| Conte, D | 1 |
| Caraceni, MP | 1 |
| Duriez, J | 1 |
| Mandelli, C | 1 |
| Corghi, E | 1 |
| Cesana, M | 1 |
| Ortolani, S | 1 |
| Bianchi, PA | 1 |
| Kruse, K | 1 |
| Büsse, M | 1 |
| Kracht, U | 1 |
| Kruse, U | 1 |
| Wohlfart, K | 1 |
| Reginster, JY | 1 |
| Denis, D | 1 |
| Albert, A | 1 |
| Deroisy, R | 1 |
| Lecart, MP | 1 |
| Fontaine, MA | 1 |
| Lambelin, P | 1 |
| Thomsen, K | 2 |
| Riis, BJ | 3 |
| Johansen, JS | 2 |
| McIntosh, J | 1 |
| Ouyang, PC | 1 |
| Chow, SN | 1 |
| Huang, SC | 1 |
| Hsieh, CY | 1 |
| Johansen, J | 1 |
| Polley, KJ | 1 |
| Horowitz, H | 1 |
| Mazzuoli, GF | 1 |
| Gennari, C | 8 |
| Minisola, S | 2 |
| Antonelli, R | 2 |
| Valtorta, C | 1 |
| Cervellin, GF | 1 |
| Gonnelli, S | 2 |
| Francini, G | 1 |
| González, D | 1 |
| Ghiringhelli, G | 1 |
| Mautalen, C | 1 |
| Hartley, TF | 2 |
| Pavlova, L | 1 |
| Stankova, G | 1 |
| Andonova, S | 1 |
| Wishart, J | 1 |
| Civitelli, R | 1 |
| Zacchei, F | 1 |
| Bigazzi, S | 1 |
| Avioli, LV | 1 |
| Gnudi, S | 1 |
| Mongiorgi, R | 1 |
| Moroni, A | 1 |
| Bertocchi, G | 1 |
| Leung, DY | 1 |
| Key, L | 1 |
| Young, MC | 1 |
| Von Deck, M | 1 |
| Wilkinson, R | 2 |
| Geha, RS | 1 |
| Davie, MW | 1 |
| Britton, JM | 1 |
| Haddaway, M | 1 |
| McCall, IW | 1 |
| Duda, RJ | 1 |
| Kumar, R | 1 |
| Nelson, KI | 1 |
| Zinsmeister, AR | 1 |
| Mann, KG | 1 |
| Pospíchal, J | 1 |
| Presl, J | 1 |
| Cantatore, FP | 1 |
| Magli, DM | 1 |
| Pipitone, V | 1 |
| Pødenphant, J | 1 |
| Leth, A | 1 |
| Berhel, M | 1 |
| Caulin, F | 1 |
| Jackson, JA | 1 |
| Kleerekoper, M | 1 |
| Rao, DS | 1 |
| Villanueva, AR | 1 |
| Frame, B | 1 |
| Larking, PW | 1 |
| McDonald, BW | 1 |
| Taylor, ML | 1 |
| Kirkland, AD | 1 |
| Deacon, AC | 1 |
| Hulme, P | 1 |
| Green, JR | 1 |
| Tellez, M | 1 |
| Gambella, GR | 1 |
| Zunino, M | 1 |
| Gallwas, K | 1 |
| Hoekman, K | 1 |
| Peters, AC | 1 |
| Bijvoet, OL | 1 |
| Gürkan, L | 1 |
| Ekeland, A | 1 |
| Gautvik, KM | 1 |
| Langeland, N | 1 |
| Rønningen, H | 1 |
| Solheim, LF | 1 |
| Hernández Díez, ER | 1 |
| Núñez-Torrón, M | 1 |
| Torrubiano Aranguren, J | 1 |
| Mazzuoli, G | 1 |
| Abdalla, HI | 1 |
| Hooke, A | 1 |
| Taylor, WH | 1 |
| Rojanasathit, S | 1 |
| Rosenberg, E | 1 |
| Haddad, JG | 1 |
| Rommel, K | 2 |
| Fourie, L | 1 |
| Böhm, W | 1 |
| Adam, WE | 1 |
| Benecke, G | 1 |
| Deshayes, P | 1 |
| Arinal, C | 1 |
| Dreyfus, P | 1 |
| Dryll, A | 1 |
| Hubault, A | 1 |
| Matrajt, H | 2 |
| de Sèze, S | 4 |
| Larsson, SE | 2 |
| Vejlens, L | 2 |
| Kaiser, G | 1 |
| Kyselka, R | 1 |
| Mühlbach, R | 5 |
| Hirthe, D | 2 |
| Beck, O | 1 |
| Schramm, G | 1 |
| Lindenhayn, K | 5 |
| Morii, H | 2 |
| Tanae, A | 1 |
| Ibayashi, H | 1 |
| Nakao, K | 1 |
| Fischer, JA | 1 |
| Mattsson, S | 1 |
| Hioco, D | 4 |
| Tun Chot, S | 1 |
| Russell, RG | 1 |
| Hodgkinson, A | 1 |
| Schwartz, E | 1 |
| Wiedemann, E | 1 |
| Simon, S | 1 |
| Schiffer, M | 1 |
| Orimo, H | 2 |
| Yoshikawa, M | 2 |
| Hayano, K | 1 |
| Sakurada, T | 1 |
| Schmidt, UJ | 3 |
| Brüschke, G | 2 |
| Kalbe, I | 2 |
| Reitzig, P | 2 |
| Grossmann, I | 2 |
| Pak, CY | 4 |
| Ihle, R | 1 |
| Knappe, G | 1 |
| Winkler, G | 1 |
| Burkhardt, H | 1 |
| Bianchi, GS | 1 |
| Meunier, P | 2 |
| Courpron, P | 2 |
| Bernard, J | 2 |
| Vignon, G | 1 |
| Lejeune, E | 1 |
| Ruitton, P | 1 |
| Orgiazzi, J | 1 |
| Bartter, FC | 5 |
| Bordier, P | 1 |
| Berbir, N | 1 |
| Bordier, PJ | 1 |
| Lozano-Tonkin, C | 1 |
| Schneider, C | 1 |
| Sommer, E | 1 |
| Neunier, P | 1 |
| Bourret, J | 1 |
| Melick, RA | 2 |
| Martin, TJ | 2 |
| Storey, E | 1 |
| Nichols, G | 2 |
| Flanagan, B | 2 |
| Johnson, JW | 1 |
| Hampers, CL | 1 |
| Merrill, JP | 1 |
| Caniggia, A | 6 |
| Hänninen, P | 1 |
| Wendelin, H | 1 |
| Räsänen, O | 1 |
| Panelius, M | 1 |
| Griffith, ER | 1 |
| Stonebridge, JB | 1 |
| Lehmann, JF | 1 |
| Heylen, H | 1 |
| Van Steenkiste, J | 1 |
| Vroninkx, R | 1 |
| Singer, FR | 2 |
| Aldred, JP | 1 |
| Neer, RM | 1 |
| Potts, JT | 1 |
| Bloch, KJ | 1 |
| Liakakos, D | 2 |
| Vlachos, P | 1 |
| Anoussakis, C | 1 |
| Longstreth, PL | 2 |
| Malinak, LR | 2 |
| Hill, CS | 1 |
| Hantman, DA | 1 |
| Donaldson, CL | 2 |
| Friedman, R | 1 |
| Thompson, RC | 1 |
| Denis, F | 1 |
| Brodaty, I | 1 |
| Chlud, K | 1 |
| Hähnel, H | 1 |
| Simon, L | 1 |
| Regal, R | 1 |
| Rossi, M | 1 |
| Claustre, J | 1 |
| Blotman, F | 1 |
| Lutwak, L | 1 |
| Urist, MR | 1 |
| Brown, DM | 1 |
| Bradford, DS | 1 |
| Palmieri, GM | 1 |
| Dvorak, J | 1 |
| Bottomley, R | 1 |
| Ege, P | 1 |
| Yoshikawa, H | 1 |
| Skosey, JL | 1 |
| Muldowney, FP | 1 |
| Donohoe, J | 1 |
| Ryan, C | 1 |
| Smith, R | 1 |
| Shai, F | 1 |
| Baker, RK | 1 |
| Cohen, RD | 1 |
| Jha, GJ | 1 |
| Deo, MG | 1 |
| Ramalingaswami, V | 1 |
| Courvoisier, B | 2 |
| Zender, R | 2 |
| Johnson, KA | 1 |
| Draper, HH | 1 |
| Sie, TL | 1 |
| Bergan, JG | 1 |
| Henneman, DH | 1 |
| Lifschitz, MD | 2 |
| Sanzenbacher, L | 1 |
| Reshef, A | 3 |
| Schwartz, A | 3 |
| Ben-Menachem, Y | 2 |
| Menczel, J | 3 |
| Guggenheim, K | 3 |
| Taylor, WF | 1 |
| McCall, JT | 1 |
| Sessler, AD | 1 |
| Vasiukova, EA | 1 |
| Kochergina, II | 1 |
| Uitto, J | 1 |
| Tani, P | 1 |
| Pihko, H | 1 |
| Bayers, JH | 1 |
| Friedman, RJ | 1 |
| Rosen, SN | 1 |
| Ahnfeldt-Mollerup, I | 1 |
| Guncaga, J | 1 |
| Lentner, C | 1 |
| Kocher, P | 1 |
| Bencini, M | 2 |
| Cesari, L | 2 |
| Borrello, G | 2 |
| Arcangeli, P | 1 |
| Toccafondi, R | 1 |
| Henneman, D | 1 |
| Pilch, Y | 1 |
| Thiébaud, M | 1 |
| Bernstein, DS | 1 |
| Hegsted, M | 1 |
| Stare, FJ | 2 |
| Eisinger, J | 1 |
| Laponche, AM | 1 |
| Moulard, JC | 1 |
| Serratrice, G | 1 |
| Recordier, AM | 1 |
| Hegsted, DM | 1 |
| Raab, W | 2 |
| Czitober, H | 1 |
| Young, MM | 1 |
| Karpouzas, J | 1 |
| Agathopoulos, A | 1 |
| Kanefield, DG | 1 |
| Heiple, KG | 1 |
| Wagner, A | 1 |
| Jones, JD | 1 |
| Maher, FT | 1 |
| Rubegni, M | 1 |
| Forconi, S | 1 |
| Romano, S | 1 |
| Horwith, M | 1 |
| Buchanan, JR | 1 |
| Gudmundsson, ST | 1 |
| Mautalen, CA | 1 |
| Charvát, J | 1 |
| Banno', S | 1 |
| Maggi, GC | 1 |
| Buzzetti, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation[NCT00580788] | Early Phase 1 | 14 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation[NCT00377312] | Early Phase 1 | 11 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/gm creatinine collected on day 7 of PTHrP infusion (NCT00580788)
Timeframe: 24 hours
| Intervention | mg/gm creatinine (Mean) |
|---|---|
| Group 1 | 121.64 |
| Group 2 | 283.43 |
| Group 3 | 320.23 |
DLT was defined as achieving one major criterion or two minor criteria rated at ≥ 2 on a scale of 0-5. The major criteria were defined as symptomatic orthostatic hypotension (systolic BP fall >30 mm/hg), tachycardia (pulse > 120), hypertension (systolic BP >160 mm/hg on 2 occasions), hypercalcemia (serum calcium ≥ 12 mg/dl), and hypophosphatemia (serum phosphorous < 1.5 mg/dl). Minor criteria included symptoms such as flushing, nausea, abdominal or muscle cramps, dizziness, lightheadedness, palpitations, etc. (NCT00580788)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
| Group 3 | 2 |
| Group 4 | 2 |
pg/ml (NCT00580788)
Timeframe: Baseline and Daily through day 8 then at follow-up visit
| Intervention | pg/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 34.13 | 38.40 | 30.13 | 32.23 | 32.27 | 42.77 | 40.53 | 32.37 | 40.10 |
| Group 2 | 45.08 | 45.88 | 36.58 | 40.38 | 46.40 | 34.90 | 37.12 | 33.43 | 45.78 |
| Group 3 | 39.0 | 39.77 | 36.73 | 35.17 | 32.07 | 35.37 | 31.17 | 30.63 | 36.33 |
% change from baseline (NCT00580788)
Timeframe: Baseline, Daily, and 1 week follow-up
| Intervention | % change (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0.00 | -1.05 | -6.83 | -12.16 | -5.63 | -8.42 | -12.59 | -16.03 | -7.12 |
| Group 2 | 0.00 | -17.49 | -30.44 | -25.66 | -21.27 | -31.71 | -30.98 | -36.60 | 0.60 |
| Group 3 | 0.00 | -23.88 | -37.77 | -39.44 | -45.04 | -39.55 | -39.88 | -38.53 | 46.67 |
% change from baseline (NCT00580788)
Timeframe: Baseline, Daily, and 1 week follow-up
| Intervention | % change (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0.00 | -12.53 | -6.35 | -5.82 | -0.33 | -8.16 | -11.91 | -7.80 | -1.25 |
| Group 2 | 0.00 | -1.17 | -1.44 | -3.79 | -9.64 | -10.88 | -16.78 | -14.01 | 6.16 |
| Group 3 | 0.00 | 24.54 | 34.77 | 19.49 | 13.61 | 9.02 | 9.86 | 15.27 | 18.23 |
% calculated from daily second morning void (NCT00580788)
Timeframe: daily
| Intervention | % of filtered load (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Group 1 | 1.93 | 1.31 | 1.07 | 1.57 | 3.05 | 3.37 | 2.72 |
| Group 2 | 2.57 | 2.26 | 2.85 | 2.79 | 2.05 | 2.75 | 3.94 |
| Group 3 | 2.38 | 4.11 | 3.27 | 2.14 | 3.12 | 5.42 | 4.13 |
mg/dl (NCT00580788)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| baseline | 11P DAY 1 | 7A DAY 2 | 3P DAY 2 | 11P DAY 2 | 7A DAY 3 | 3P DAY 3 | 11P DAY 3 | 7A DAY 4 | 3P DAY 4 | 11P DAY 4 | 7A DAY 5 | 3P DAY 5 | 11P DAY 5 | 7A DAY 6 | 3P DAY 6 | 11P DAY 6 | 7A DAY 7 | 3P DAY 7 | 11P DAY 7 | 7A DAY 8 | FOLLOW-UP | |
| Group 1 | 4.79 | 4.51 | 4.77 | 4.52 | 4.48 | 4.77 | 4.73 | 4.41 | 4.75 | 4.45 | 4.47 | 4.71 | 4.61 | 4.60 | 4.63 | 4.72 | 4.32 | 4.55 | 4.84 | 4.56 | 5.00 | 4.68 |
| Group 2 | 4.72 | 4.77 | 4.98 | 4.99 | 5.04 | 5.31 | 4.99 | 4.58 | 4.90 | 4.68 | 4.46 | 4.82 | 4.67 | 4.58 | 4.77 | 4.83 | 4.72 | 5.01 | 5.04 | 4.87 | 5.43 | 4.83 |
| Group 3 | 4.55 | 4.75 | 5.07 | 5.07 | 4.84 | 5.25 | 4.91 | 4.83 | 5.11 | 4.72 | 4.69 | 4.97 | 4.87 | 4.79 | 5.25 | 5.35 | 5.19 | 5.55 | 5.25 | 5.24 | 5.69 | 4.80 |
pg/ml (NCT00580788)
Timeframe: Baseline and Daily
| Intervention | pg/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 42.97 | 23.47 | 21.43 | 26.77 | 22.37 | 21.13 | 19.40 | 12.60 | 56.37 |
| Group 2 | 30.70 | 7.82 | 5.23 | 7.88 | 7.54 | 6.57 | 5.67 | 3.00 | 31.60 |
| Group 3 | 48.27 | 3.60 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 44.20 |
% change from baseline (NCT00580788)
Timeframe: Baseline, Daily, and 1 week follow-up
| Intervention | % change (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0.00 | 32.86 | 26.73 | 28.32 | 41.29 | 11.41 | 35.04 | 65.77 | -14.95 |
| Group 2 | 0.00 | 87.75 | 91.53 | 90.86 | 82.36 | 123.08 | 161.55 | 214.90 | -3.33 |
| Group 3 | 0.00 | 54.21 | 88.51 | 89.57 | 116.58 | 150.82 | 176.42 | 108.69 | -9.02 |
% change from baseline (NCT00580788)
Timeframe: Baseline, Daily, and 1 week follow-up
| Intervention | % change (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0.00 | 59.78 | 66.67 | 71.19 | 79.39 | 74.09 | 109.27 | 110.61 | -35.73 |
| Group 2 | 0.00 | 147.12 | 180.27 | 167.01 | 167.27 | 239.51 | 283.15 | 368.31 | -8.60 |
| Group 3 | 0.00 | 105.06 | 148.45 | 165.16 | 174.58 | 230.42 | 267.89 | 140.58 | -41.33 |
mg/dl (NCT00580788)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| baseline | 11P DAY 1 | 7A DAY 2 | 3P DAY 2 | 11P DAY 2 | 7A DAY 3 | 3P DAY 3 | 11P DAY 3 | 7A DAY 4 | 3P DAY 4 | 11P DAY 4 | 7A DAY 5 | 3P DAY 5 | 11P DAY 5 | 7A DAY 6 | 3P DAY 6 | 11P DAY 6 | 7A DAY 7 | 3P DAY 7 | 11P DAY 7 | 7A DAY 8 | FOLLOW-UP | |
| Group 1 | 3.55 | 3.87 | 4.07 | 3.63 | 4.13 | 3.90 | 3.53 | 4.03 | 4.07 | 3.90 | 3.67 | 3.87 | 3.57 | 3.93 | 4.00 | 3.67 | 3.93 | 4.30 | 4.07 | 4.20 | 4.43 | 3.57 |
| Group 2 | 3.63 | 3.90 | 4.20 | 3.50 | 3.52 | 3.77 | 3.53 | 3.58 | 3.90 | 3.37 | 3.48 | 4.02 | 3.35 | 3.45 | 4.00 | 3.80 | 3.90 | 4.28 | 3.62 | 3.62 | 4.10 | 3.48 |
| Group 3 | 3.55 | 4.03 | 3.63 | 3.70 | 3.63 | 3.43 | 3.60 | 3.70 | 3.30 | 3.33 | 3.63 | 3.20 | 3.10 | 3.87 | 3.63 | 3.73 | 3.93 | 3.73 | 3.50 | 3.60 | 3.40 | 3.87 |
mg/dl (NCT00580788)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| baseline | 11P DAY 1 | 7A DAY 2 | 3P DAY 2 | 11P DAY 2 | 7A DAY 3 | 3P DAY 3 | 11P DAY 3 | 7A DAY 4 | 3P DAY 4 | 11P DAY 4 | 7A DAY 5 | 3P DAY 5 | 11P DAY 5 | 7A DAY 6 | 3P DAY 6 | 11P DAY 6 | 7A DAY 7 | 3P DAY 7 | 11P DAY 7 | 7A DAY 8 | FOLLOW-UP | |
| Group 1 | 9.37 | 9.67 | 9.4 | 9.57 | 9.67 | 9.6 | 9.73 | 9.40 | 9.47 | 9.40 | 9.37 | 9.30 | 9.50 | 9.43 | 9.57 | 9.43 | 9.43 | 9.40 | 9.70 | 9.60 | 9.83 | 9.33 |
| Group 2 | 9.58 | 9.80 | 10.05 | 10.28 | 10.32 | 10.40 | 10.42 | 9.73 | 10.00 | 9.92 | 9.48 | 9.62 | 9.83 | 9.45 | 9.83 | 10.08 | 9.67 | 10.13 | 10.22 | 10.27 | 10.67 | 9.80 |
| Group 3 | 9.2 | 9.67 | 10.17 | 10.47 | 10.23 | 10.73 | 10.67 | 9.93 | 10.3 | 10.33 | 10.00 | 10.53 | 10.27 | 9.80 | 10.53 | 10.83 | 10.43 | 10.90 | 10.70 | 10.73 | 11.17 | 9.17 |
mg/dl calculated from daily second morning void (NCT00580788)
Timeframe: daily
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
| Group 1 | 3.43 | 4.48 | 4.28 | 4.42 | 4.43 | 4.90 | 4.15 |
| Group 2 | 3.91 | 4.08 | 3.74 | 3.75 | 3.95 | 3.98 | 3.98 |
| Group 3 | 3.38 | 3.47 | 3.25 | 3.15 | 3.37 | 3.38 | 2.95 |
mg/gm creatinine (NCT00377312)
Timeframe: 24 hours period from Day 7 to Day 8
| Intervention | mg/gm creatinine (Mean) |
|---|---|
| Group 1 | 315.278845 |
| Group 2 | 210.24827 |
DLT was defined as achieving one major criterion or two minor criteria rated at ≥ 2 on a scale of 0-5. The major criteria were defined as symptomatic orthostatic hypotension (systolic BP fall >30 mm/hg), tachycardia (pulse > 120), hypertension (systolic BP >160 mm/hg on 2 occasions), hypercalcemia (serum calcium ≥ 12 mg/dl), and hypophosphatemia (serum phosphorous < 1.5 mg/dl). Minor criteria included symptoms such as flushing, nausea, abdominal or muscle cramps, dizziness, lightheadedness, palpitations, etc. (NCT00377312)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
| Group 2 | 2 |
pg/ml (NCT00377312)
Timeframe: baseline, daily up to Day 8 and follow-up
| Intervention | pg/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 37.78 | 40.90 | 35.68 | 27.70 | 36.16 | 38.00 | 32.18 | 34.78 | 37.06 |
| Group 2 | 39.18 | 42.72 | 41.74 | 34.72 | 31.53 | 35.68 | 28.48 | 33.13 | 40.16 |
% change from baseline (NCT00377312)
Timeframe: baseline, daily, one week follow-up
| Intervention | % change from baseline (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0 | -18.536953 | -31.14427 | -32.942391 | -31.506308 | -36.35864 | -40.709396 | -39.046467 | 31.4333667 |
| Group 2 | 0 | -16.118573 | -35.577655 | -35.018736 | -35.309609 | -35.064188 | -30.58629 | -35.619862 | 26.3367446 |
% change from baseline (NCT00377312)
Timeframe: baseline, daily, one week follow-up
| Intervention | % change from baseline (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0 | 7.35 | -5.61 | 4.34 | -8.75 | -3.42 | -1.35 | 2.09 | 14.08 |
| Group 2 | 0 | 7.91 | 9.05 | 0.77 | -2.19 | -8.89 | -13.72 | -9.91 | 5.51 |
% = (S Creatinine X U Calcium)/(S Calcium X U Creatinine) (NCT00377312)
Timeframe: baseline and daily
| Intervention | % of excretion (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 8 | |
| Group 1 | 3.38 | 2.83 | 4.28 | 2.82 | 3.90 | 4.44 | 5.54 |
| Group 2 | 1.80 | 2.87 | 3.76 | 3.87 | 2.54 | 3.49 | 4.58 |
mg/dl (NCT00377312)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 11P Day 1 | 7 A Day 2 | 3P Day 2 | 11P Day 2 | 7A Day 3 | 3P Day 3 | 11P Day 3 | 7A Day 4 | 3P Day 4 | 11P Day 4 | 7A Day 5 | 3P Day 5 | 11P Day 5 | 7A Day 6 | 3P Day 6 | 11P Day 6 | 7A Day 7 | 3P Day 7 | 11P Day 7 | 7A Day 8 | FOLLOW-UP | |
| Group 1 | 4.72 | 4.93 | 5.17 | 5.08 | 5.01 | 5.21 | 5.08 | 4.80 | 5.10 | 4.86 | 4.93 | 5.18 | 5.03 | 4.90 | 5.29 | 5.17 | 5.02 | 5.20 | 4.89 | 5.15 | 5.34 | 4.79 |
| Group 2 | 4.52 | 4.54 | 5.04 | 5.01 | 4.97 | 5.22 | 5.11 | 4.82 | 4.90 | 4.77 | 4.70 | 4.84 | 4.91 | 4.68 | 4.95 | 4.89 | 4.82 | 4.99 | 4.88 | 4.86 | 5.28 | 4.70 |
pg/ml (NCT00377312)
Timeframe: baseline, daily up to Day 8 and follow-up
| Intervention | pg/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 20.90 | 3.86 | 3.00 | 4.12 | 4.64 | 3.50 | 3.58 | 3.09 | 23.60 |
| Group 2 | 52.44 | 5.30 | 3.38 | 5.00 | 11.68 | 6.34 | 6.68 | 3.00 | 35.20 |
% change from baseline (NCT00377312)
Timeframe: baseline, daily, one week follow-up
| Intervention | % change from baseline (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0 | 61.8428952 | 85.7699521 | 96.3668762 | 107.517148 | 150.594712 | 141.193285 | 153.72039 | 4.06445076 |
| Group 2 | 0 | 77.4709521 | 85.9288044 | 59.9595445 | 83.3701575 | 120.268081 | 109.660098 | 148.451289 | 1.05486408 |
% change from baseline (NCT00377312)
Timeframe: baseline, daily, one week follow-up
| Intervention | % change from baseline (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | follow-up | |
| Group 1 | 0 | 113.70 | 136.76 | 142.66 | 165.97 | 205.39 | 206.06 | 225.04 | -6.78 |
| Group 2 | 0 | 104.07 | 112.11 | 70.74 | 92.13 | 141.66 | 168.77 | 244.50 | -11.82 |
mg/dl (NCT00377312)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 11P Day 1 | 7 A Day 2 | 3P Day 2 | 11P Day 2 | 7A Day 3 | 3P Day 3 | 11P Day 3 | 7A Day 4 | 3P Day 4 | 11P Day 4 | 7A Day 5 | 3P Day 5 | 11P Day 5 | 7A Day 6 | 3P Day 6 | 11P Day 6 | 7A Day 7 | 3P Day 7 | 11P Day 7 | 7A Day 8 | FOLLOW-UP | |
| Group 1 | 3.51 | 4.16 | 3.78 | 3.82 | 3.86 | 3.68 | 3.68 | 3.86 | 3.58 | 3.38 | 3.76 | 3.56 | 3.70 | 3.56 | 3.86 | 3.78 | 3.70 | 3.70 | 3.12 | 3.48 | 3.82 | 4.12 |
| Group 2 | 3.45 | 3.78 | 3.68 | 3.44 | 3.78 | 3.58 | 3.28 | 3.60 | 3.64 | 3.22 | 3.52 | 3.72 | 3.22 | 3.64 | 3.60 | 3.03 | 3.63 | 3.90 | 3.18 | 3.55 | 3.80 | 3.64 |
mg/dl (NCT00377312)
Timeframe: 12 hours after the infusion was started then q 8 hours for 7 days, Follow-up 1 week after infusion complete
| Intervention | mg/dl (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 11P Day 1 | 7 A Day 2 | 3P Day 2 | 11P Day 2 | 7A Day 3 | 3P Day 3 | 11P Day 3 | 7A Day 4 | 3P Day 4 | 11P Day 4 | 7A Day 5 | 3P Day 5 | 11P Day 5 | 7A Day 6 | 3P Day 6 | 11P Day 6 | 7A Day 7 | 3P Day 7 | 11P Day 7 | 7A Day 8 | FOLLOW-UP | |
| Group 1 | 9.33 | 9.56 | 9.74 | 10.14 | 9.84 | 10.10 | 10.32 | 9.72 | 10.04 | 9.94 | 9.54 | 10.16 | 10.26 | 9.82 | 10.18 | 10.28 | 9.56 | 10.18 | 10.02 | 9.82 | 10.38 | 9.50 |
| Group 2 | 9.11 | 9.78 | 10.06 | 10.30 | 10.38 | 10.52 | 10.66 | 9.94 | 9.88 | 9.94 | 9.56 | 9.64 | 9.72 | 9.46 | 9.92 | 10.28 | 9.60 | 9.90 | 9.98 | 10.03 | 10.50 | 9.50 |
mg/dl (NCT00377312)
Timeframe: baseline and daily
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| baseline | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 8 | |
| Group 1 | 3.80 | 3.28 | 3.37 | 3.25 | 3.19 | 3.45 | 3.52 |
| Group 2 | 3.50 | 3.30 | 3.11 | 3.66 | 3.31 | 3.25 | 3.43 |
26 reviews available for hydroxyproline and Osteoporosis
| Article | Year |
|---|---|
[Bone and Nutrition. Functional foods for bone and cartilage tissues : Evidence for the action of collagen peptides].
Topics: Animals; Bone and Bones; Bone Density; Cartilage; Cell Differentiation; Cell Proliferation; Chondroc | 2015 |
[Osteoporosis--pathophysiology and laboratory diagnostic methods].
Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Collagen T | 2010 |
Bone markers: biochemical and clinical significance.
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Remodeling; Bone Resorption; Hum | 2004 |
Osteoporosis and osteomalacia.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Calcium; Estrogens; Female; Fractures, Bone; Huma | 1980 |
[Development, chemistry, and clinical pharmacology of fully synthetic human calcitonin (author's transl)].
Topics: Alkaline Phosphatase; Calcitonin; Calcium; Humans; Hydroxyproline; Kidney; Osteitis Deformans; Osteo | 1982 |
Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcinosis; Clinical Trials as Topic; Clodronic Acid; Dose | 1994 |
[Biochemical diagnosis of osteoporosis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Calcium; Collagen; Humans; Hydroxyproline; Osteocalcin; Oste | 1994 |
Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis.
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium; Female; Hip F | 1993 |
[Biological markers of bone metabolism].
Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Calcium; Female; Hu | 1993 |
Clinical guidelines for the treatment of osteoporosis in Japan.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Calcium; Female; Fractures, | 1996 |
[Biochemical markers for bone metabolism--overview].
Topics: Acid Phosphatase; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; C | 2002 |
[Primary hyperparthyroidism. Analysis of 152 patients with special reference to acute life threatening complications (acute hyperparathyroidism)].
Topics: Acute Disease; Adenoma; Adolescent; Adrenal Glands; Adult; Aged; Alkaline Phosphatase; Body Weight; | 1976 |
Ageing of bone: its relation to osteoporosis and osteoarthrosis in post-menopausal women.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Bone and Bones; Bone Development; Bone Diseases; Cal | 1975 |
Osteoporosis as the presenting sign of leukemic relapse in an adolescent: case report and literature review.
Topics: Adolescent; Calcitonin; Calcitriol; Calcium; Humans; Hydroxyproline; Male; Osteoporosis; Precursor C | 1992 |
Growth hormone and adult bone remodelling.
Topics: Adult; Bone Remodeling; Growth Hormone; Humans; Hydroxyproline; Osteoblasts; Osteocalcin; Osteoclast | 1991 |
Calcium and osteoporosis.
Topics: Bone Resorption; Calcium; Calcium, Dietary; Female; Humans; Hydroxyproline; Menopause; Nutritional R | 1988 |
[Bone metabolism disorders. Pathogenesis and diagnosis].
Topics: Alkaline Phosphatase; Bone Diseases; Calcium; Diagnosis, Differential; Humans; Hydroxyproline; Hyper | 1972 |
Parathyroid hormone and thyrocalcitonin: their mode of action and regulation.
Topics: Adenoma; Adenylyl Cyclases; Adult; Animals; Biological Transport; Bone and Bones; Bone Resorption; C | 1971 |
[Problems concerning clinical application of calcitonin].
Topics: Adult; Aged; Alkaline Phosphatase; Calcitonin; Calcium; Child, Preschool; Female; Fibrous Dysplasia | 1972 |
Current methods of in-vivo measurement of osteoporosis.
Topics: Absorptiometry, Photon; Activation Analysis; Biopsy; Bone and Bones; Calcium; Calcium Isotopes; Huma | 1973 |
[Urine hydroxyproline a review].
Topics: Acromegaly; Bone Resorption; Carbon Isotopes; Collagen; Humans; Hydroxyproline; Hyperthyroidism; Hyp | 1968 |
[Bone changes in hyperparathyroidism].
Topics: Adult; Bone and Bones; Bone Resorption; Calcium; Diagnosis, Differential; Female; Humans; Hydroxypro | 1969 |
Some basic aspects of bone metabolism in relation to osteoporosis.
Topics: Age Factors; Aged; Ascorbic Acid; Black People; Bone and Bones; Bone Regeneration; Bone Resorption; | 1970 |
Bone disease in intestinal malabsorption.
Topics: Bone and Bones; Bone Diseases; Calcium; Humans; Hydroxyproline; Hyperparathyroidism; Hypoparathyroid | 1970 |
Recent advances in the unerstanding and management of metabolic bone disease.
Topics: Bone Diseases; Calcitonin; Collagen; Homocystinuria; Humans; Hydroxyproline; Hyperparathyroidism; Me | 1970 |
Some aspects of metabolic bone disease related to rheumatology.
Topics: Absorptiometry, Photon; Adult; Aged; Aging; Bone Diseases; Bone Resorption; Calcium; Child; Estrogen | 1971 |
31 trials available for hydroxyproline and Osteoporosis
| Article | Year |
|---|---|
Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.
Topics: Aged; Calcitriol; Calcium; Clinical Trials as Topic; Dihydroxycholecalciferols; Estrogens, Conjugate | 1980 |
Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Clinical Trials as Topic; Estradiol; Estriol; Est | 1984 |
Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women.
Topics: Aged; Bone and Bones; Calcium, Dietary; Creatinine; Female; Humans; Hydroxyproline; Menopause; Middl | 1984 |
Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis.
Topics: Bone Resorption; Calcium; Climacteric; Clinical Trials as Topic; Double-Blind Method; Female; Hormon | 1980 |
An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Development; Bone Resorption; Calcitonin; | 1993 |
An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Development; Bone Resorption; Calcitonin; | 1993 |
An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Development; Bone Resorption; Calcitonin; | 1993 |
An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Development; Bone Resorption; Calcitonin; | 1993 |
[Clinical observation of osteoporosis in adolescents].
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone and Bones; Bone Density; Child; Female; Humans; Hydr | 2000 |
Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation.
Topics: Adrenal Cortex Hormones; Adult; Calcitriol; Calcium; Cyclosporine; Etidronic Acid; Female; Fractures | 2001 |
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Brain Injuries; Calcium; Castration; C | 1976 |
[Therapy of senile osteoporosis using sodium fluoride--continuous and intermittent long-term therapy].
Topics: Age Factors; Aged; Densitometry; Female; Fluorides; Humans; Hydroxyproline; Long-Term Care; Male; Me | 1979 |
The effect of 1alpha-hydroxycholecalciferol and hormone therapy on the calcium balance of post-menopausal osteoporosis.
Topics: Bone and Bones; Bone Regeneration; Bone Resorption; Calcium; Clinical Trials as Topic; Ethinyl Estra | 1977 |
Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.
Topics: Adult; Bone and Bones; Bone Regeneration; Bone Resorption; Clinical Trials as Topic; Creatinine; Dou | 1978 |
Bone loss during oestriol therapy in postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; Creatine; Double-Bli | 1979 |
Effect of ipriflavone on bone mass in elderly osteoporotic women.
Topics: Aged; Aged, 80 and over; Bone Density; Creatinine; Double-Blind Method; Female; Humans; Hydroxyproli | 1992 |
Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis.
Topics: Aged; Bone Development; Bone Resorption; Calcitriol; Calcium; Female; Humans; Hydroxyproline; Middle | 1991 |
Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
Topics: Aged; Alkaline Phosphatase; Calcitonin; Calcitriol; Calcium; Calcium Radioisotopes; Cyclic AMP; Drug | 1990 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Adult; Alkaline Phosphatase; Calcitriol; Clinical Trials as Topic; Diphosphonates; Female; Glucocort | 1990 |
Effect of etidronate disodium on bone turnover following surgical menopause.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Calcium-Binding Proteins; Etidronic Acid; Female; Hum | 1989 |
Transdermal estradiol in the treatment of postmenopausal bone loss.
Topics: Administration, Cutaneous; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; | 1989 |
[Disorders of calcium and bone metabolism in glucocorticoid treatment].
Topics: Adolescent; Adrenocorticotropic Hormone; Bone Resorption; Calcium; Child; Child, Preschool; Dexameth | 1988 |
1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
Topics: Administration, Intranasal; Bone and Bones; Calcitonin; Calcium; Clinical Trials as Topic; Creatinin | 1987 |
Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium-Binding Proteins; Clinical Trials as | 1987 |
Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.
Topics: Alkaline Phosphatase; Biochemical Phenomena; Biochemistry; Bone and Bones; Calcium; Calcium-Binding | 1988 |
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
Topics: Aged; Bone and Bones; Calcitonin; Calcium; Clinical Trials as Topic; Creatinine; Double-Blind Method | 1986 |
Densitometric analysis in in vivo evaluation of synthetic salmon calcitonin activity.
Topics: Aged; Aging; Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium Carbonate; Densitometry; Fema | 1988 |
Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Topics: Administration, Oral; Alkaline Phosphatase; Biopsy; Bone and Bones; Calcitonin; Calcium; Clinical Tr | 1986 |
Calcitonin and treatment of osteoporosis.
Topics: Bone and Bones; Calcitonin; Calcium; Clinical Trials as Topic; Humans; Hydroxyproline; Osteoporosis; | 1985 |
Prevention of bone mineral loss in postmenopausal women by norethisterone.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Creatinine; Drug Evaluation; Female; Humans; Hydroxyp | 1985 |
Estrogenic antagonism of metabolic effects of administered growth hormone.
Topics: Adult; Bone Resorption; Calcium; Clinical Trials as Topic; Estrogens, Conjugated (USP); Ethinyl Estr | 1969 |
Sites and modes of action of an estrogen-gestagen combination on calcium and phosphate metabolism in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Isotopes; C | 1972 |
The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
Topics: Aged; Alkaline Phosphatase; Animals; Audiometry; Bone and Bones; Bone Resorption; Calcitonin; Calciu | 1971 |
Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Resorption; Calcitonin; Calcium; Calcium Isotope | 1971 |
241 other studies available for hydroxyproline and Osteoporosis
| Article | Year |
|---|---|
MicroRNA-497 elevation or LRG1 knockdown promotes osteoblast proliferation and collagen synthesis in osteoporosis via TGF-β1/Smads signalling pathway.
Topics: Alkaline Phosphatase; Animals; Apoptosis; Biomarkers; Calcium; Cell Survival; Collagen; Down-Regulat | 2020 |
Preventive Effects of Evodiamine on Dexamethasone-Induced Osteoporosis in Zebrafish.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Bone Remodeling; Calcification, Physiologic; Calciu | 2019 |
Osteoporosis risk assessment using multilayered gold-nanoparticle thin film via SALDI-MS measurement.
Topics: Biomarkers; Gold; Humans; Hydroxyproline; Limit of Detection; Metal Nanoparticles; Osteoporosis; Rep | 2019 |
Antiosteoporotic activity of echinacoside in ovariectomized rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Cista | 2013 |
[Metabolic status and bone mineral density in patients with pseudarthrosis of long bones in hyperhomocysteinemia].
Topics: Adult; Bone and Bones; Bone Diseases, Metabolic; Cartilage Oligomeric Matrix Protein; Case-Control S | 2013 |
Experimental study of the effect on bone metabolism and bone histomorphometry of osteoporosis rats with birdpecking and revolving moxibustion on twelve back-shu points.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Female; Hydroxyproline; Medicine, Chine | 2015 |
Atypical thyrotropin-secreting pituitary microadenoma revealed by severe osteoporosis in a young man.
Topics: Adult; Alkaline Phosphatase; Body Height; Body Weight; Bone Density; Calcium; Carbimazole; Diphospho | 2009 |
[Biochemical diagnosis of immobilization osteoporosis].
Topics: Adult; Biomarkers; Bone Density; Female; Humans; Hydroxyproline; Hypokinesia; Male; Middle Aged; Ost | 2009 |
Prevention of osteoporosis in mice after ovariectomy via allograft of microencapsulated ovarian cells.
Topics: Alginates; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Bone and Bones; Bone Remodeling; | 2010 |
Effect of isoflavone-enriched milk on bone mass in ovariectomized rats.
Topics: Alkaline Phosphatase; Amino Acids; Animals; Bone Density; Disease Models, Animal; Female; Hydroxypro | 2009 |
Mandibular bone density and calcium content affected by different kind of stress in mice.
Topics: Adrenal Glands; Animals; Bone Density; Calcium; Disease Models, Animal; Electroshock; Hydrocortisone | 2010 |
Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Calcium; Creatinine; Female; Humans; Hydroxyproli | 2002 |
CORRELATION OF URINARY HYDROXYPROLINE, SERUM ALKALINE PHOSPHATASE AND SKELETAL CALCIUM TURNOVER.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Calcium; Geri | 1964 |
[HYDROXYLYSINES IN THE URINE IN OSTEOPATHIES WITH MARKED CHANGES IN THE BONE MATRIX].
Topics: Bone Diseases; Bone Matrix; Glycosaminoglycans; Humans; Hydroxylysine; Hydroxyproline; Kidney; Lysin | 1964 |
THE RELATION BETWEEN CALCIUM BALANCE AND HYDROXYPROLINE EXCRETION IN OSTEOPOROSIS.
Topics: Amino Acids; Body Fluids; Bone Resorption; Calcium; Calcium, Dietary; Humans; Hydroxyproline; Osteom | 1964 |
HYPOPHOSPHATEMIC RICKETS WITH RENAL HYPER-GLYCINURIA, RENAL GLUCOSURIA, AND GLYCYL-PROLINURIA. A SYNDROME WITH EVIDENCE FOR RENAL TUBULAR SECRETION OF PHOSPHORUS.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Chronic Kidney Disease-Mineral and Bone Disorder; | 1964 |
URINARY HYDROXYPROLINE LEVELS IN AN AGED POPULATION. A STUDY OF NON-OSTEOPOROTIC AND OSTEOPOROTIC PATIENTS.
Topics: Aging; Geriatrics; Humans; Hydroxyproline; Osteoporosis; Urine | 1965 |
SPINAL OSTEOPOROSIS AND THE MENOPAUSE.
Topics: Blood; Bone Resorption; Calcium; Ethinyl Estradiol; Female; Fluids and Secretions; Glycerophosphates | 1965 |
URINARY HYDROXYPROLINE EXCRETION IN MALABSORPTION STATES.
Topics: Alkaline Phosphatase; Celiac Disease; Collagen; Crohn Disease; Enteritis; Fluids and Secretions; Fra | 1965 |
Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Calcium; Cross-Section | 2005 |
Effect of zinc supplementation on ethanol-mediated bone alterations.
Topics: Animals; Bone and Bones; Central Nervous System Depressants; Dietary Supplements; Electrolytes; Etha | 2005 |
Citrus juice modulates bone strength in male senescent rat model of osteoporosis.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Antioxidants; Beverages; Bone and Bones; Bone Densi | 2006 |
Investigation of correlations occurring between the urinary excretion of calcium, nitrogen, phosphorus and hydroxyproline after calcium administration in articular disease.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Calcium; Child; Humans; Hydroxyproline; Middle Aged; Nitro | 1967 |
[A method of fractionating urinary peptides containing hydroxyproline].
Topics: Acromegaly; Arthritis, Rheumatoid; Bone Neoplasms; Chemistry, Clinical; Chromatography, Ion Exchange | 1967 |
Bone changes in Ehlers-Danlos syndrome.
Topics: Adult; Bone and Bones; Calcinosis; Ehlers-Danlos Syndrome; Female; Fluorescence; Humans; Hydroxyprol | 1967 |
Bone changes associated with glucocorticoid excess.
Topics: Adolescent; Adult; Biopsy; Bone and Bones; Bone Resorption; Collagen; Cushing Syndrome; Glucocortico | 1967 |
The treatment of adult phosphate diabetes and Fanconi syndrome with neutral sodium phosphate.
Topics: Adult; Alkaline Phosphatase; Calcium; Calcium Isotopes; Fanconi Syndrome; Female; Humans; Hydroxypro | 1967 |
The bones in chronic liver disease.
Topics: Adult; Aged; Alkaline Phosphatase; Calcium; Chronic Disease; Female; Hepatitis; Humans; Hydroxyproli | 1967 |
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Resorption; Calcium-Binding Proteins; Femal | 1984 |
[Sodium etidronate (EHDP) and osteoporosis].
Topics: Adult; Aged; Bone Resorption; Calcium; Cyclic AMP; Etidronic Acid; Female; Humans; Hydroxyproline; M | 1981 |
Sodium excess in postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Calcium; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Neutron | 1983 |
Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.
Topics: Age Factors; Aged; Body Weight; Bone Resorption; Creatinine; Estrogens; Female; Hormones; Humans; Hy | 1984 |
Urinary gamma-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Paget's disease.
Topics: 1-Carboxyglutamic Acid; Adult; Aged; Alkaline Phosphatase; Calcium; Calcium-Binding Proteins; Female | 1983 |
Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease.
Topics: Adult; Aged; Bone Diseases; Female; Fractures, Bone; Humans; Hydroxyproline; Male; Middle Aged; Mult | 1984 |
Nonosteomalacic osteopathy associated with chronic hypophosphatemia.
Topics: Adult; Alkaline Phosphatase; Bone Diseases; Calcium; Creatinine; Humans; Hydroxyproline; Kidney Calc | 1982 |
Urinary elimination of glycosaminoglycans during the immobilization osteoporosis of spinal cord injury patients.
Topics: Adult; Calcium; Female; Glycosaminoglycans; Humans; Hydroxyproline; Male; Middle Aged; Osteoporosis; | 1983 |
Smoking, the menopause and biochemical parameters of bone loss and bone turnover.
Topics: Age Factors; Bone and Bones; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; M | 1982 |
[Rarefying osteopathy in rheumatology. Methods of evaluation and comparison of urinary hydroxyproline and serum proline iminopeptidase].
Topics: Adult; Aged; Aminopeptidases; Arthritis, Rheumatoid; Bone Diseases; Female; Humans; Hydroxyproline; | 1980 |
[Prolactin and estrogens in osteoporosis in post-menopausal women (author's transl)].
Topics: Aged; Alkaline Phosphatase; Estrogens; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Osteo | 1982 |
Bone matrix and mineral abnormalities in postmenopausal osteoporosis.
Topics: Adult; Age Factors; Aged; Bone and Bones; Calcium; Carbonates; Female; Humans; Hydroxyproline; Magne | 1982 |
[Laboratory tests and bone biopsy in the diagnosis and treatment of osteoporosis].
Topics: Aged; Alkaline Phosphatase; Bone Resorption; Calcium; Female; Humans; Hydroxyproline; Male; Middle A | 1982 |
[Diminished bone turnover in patients treated with anticonvulsants].
Topics: Adolescent; Adult; Anticonvulsants; Bone Regeneration; Bone Resorption; Epilepsy; Female; Humans; Hy | 1982 |
Infrared spectroscopy and magnesium content of bone mineral in osteoporotic women.
Topics: Aged; Bone and Bones; Creatinine; Female; Humans; Hydroxyproline; Magnesium; Menopause; Middle Aged; | 1981 |
Changes in calcium absorption during hormonal replacement therapy in postmenopausal osteoporosis.
Topics: Calcium; Cyclofenil; Estradiol; Female; Humans; Hydroxyproline; Intestinal Absorption; Menopause; Mi | 1981 |
Mineral metabolism in spinal cord injury.
Topics: Adult; Bone and Bones; Bone Resorption; Calcium; Humans; Hydroxyproline; Magnesium; Male; Minerals; | 1980 |
Rise in plasma alkaline phosphatase at the menopause.
Topics: Alkaline Phosphatase; Female; Humans; Hydroxyproline; Menopause; Osteoporosis | 1980 |
The relation between bone loss and calcium balance in women.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Regeneration; Bone Resorption; Calcium; Female; Fem | 1980 |
Bone mineral content of the radius: good correlations with physicochemical determinations in iliac crest trabecular bone of normal and osteoporotic subjects.
Topics: Adult; Aged; Aging; Calcium; Densitometry; Female; Gamma Rays; Humans; Hydroxyproline; Ilium; Magnes | 1981 |
Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Calcium; Diphosphonates; Female; Humans; Hy | 1995 |
The anti-osteoporotic activity of amine-carboxyboranes in rodents.
Topics: Animals; Bone Neoplasms; Boranes; Calcium; Female; Hydroxyproline; In Vitro Techniques; Male; Mice; | 1995 |
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bon | 1995 |
Effect of age on bone density and bone turnover in men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgens; Bone Density; Bone Development; Bone Resorpt | 1995 |
Parathyroidectomy does not prevent bone loss in the oophorectomized rat.
Topics: Alkaline Phosphatase; Animals; Bone Density; Calcium; Disease Models, Animal; Female; Femur; Hydroxy | 1994 |
Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism.
Topics: Adult; Alcoholism; Bone Density; Calcium; Calcium, Dietary; Creatinine; Humans; Hydroxyproline; Live | 1993 |
Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids.
Topics: Adolescent; Arthritis, Juvenile; Bone and Bones; Bone Density; C-Reactive Protein; Calcifediol; Chil | 1993 |
Osteoporosis in lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Biological Transport; Bone and Bones; Child | 1993 |
Anabolic effects of progestogens in bone remodelling.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Remodeling; Estradiol; Female; Follow-Up St | 1995 |
[Laboratory diagnosis of metabolic osteopathy].
Topics: Adult; Aged; Alkaline Phosphatase; Bone Diseases, Metabolic; Calcium; Diagnosis, Differential; Femal | 1996 |
Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction.
Topics: Animals; Bone Density; Calcitriol; Calcium, Dietary; Diphosphonates; Dogs; Female; Hydroxyproline; O | 1996 |
Cross genotype sex hormone treatment in two cases of hypogonadal osteoporosis.
Topics: Adult; Bone Density; Estrogens; Female; Genotype; Humans; Hydroxyproline; Hypogonadism; Male; Osteop | 1997 |
Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Creatinine; Female; Fractures, Bone; Humans; Hydroxyp | 1997 |
[Changes in phospho-calcium metabolic factors in function of the rate of bone turnover. Epidemiologic study of osteoporosis (part 2)].
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density; Creatinine; Female; Humans; Hydroxy | 1996 |
Reduction of bone mass in women after bone marrow transplantation.
Topics: Adolescent; Adult; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Marrow Transplantation; | 1997 |
The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Creatinine; Female; Fluorides; Follow-Up Studies; H | 1996 |
The value of biochemical markers of bone turnover in osteoporosis.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Collagen; Female; Humans; Hydroxypr | 1997 |
[Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Resorption; Female; Hum | 1997 |
Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover.
Topics: Absorptiometry, Photon; Acid Phosphatase; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bon | 1997 |
Intestinal calcium absorption in men with spinal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Calcitriol; Calcium; Calcium Radioisotopes; Humans; Hydroxyproline; | 1998 |
Urinary collagen crosslinks reflect further bone loss of femoral neck in osteoporotic patients undergoing vitamin D therapy.
Topics: Alkaline Phosphatase; Amino Acids; Analysis of Variance; Biomarkers; Bone Density; Bone Resorption; | 1998 |
Big future in store for biochemical bone markers.
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Resorption; Humans; Hydroxyproline; Osteoporosis | 1996 |
Bone turnover associated with antler growth in red deer (Cervus elaphus).
Topics: Animals; Antlers; Bone Density; Bone Remodeling; Deer; Hydroxyproline; Ilium; Male; Microscopy, Elec | 1999 |
Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis.
Topics: 25-Hydroxyvitamin D 2; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Bone Density; Bon | 1999 |
Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat.
Topics: Amino Acids; Animals; Bone Demineralization, Pathologic; Erythrocyte Membrane; Estrogen Replacement | 1999 |
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene.
Topics: Adult; Aged; Animals; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Case-Control Studi | 2000 |
Bone resorption is increased in young adults with thalassaemia major.
Topics: Absorptiometry, Photon; Adult; Alkaline Phosphatase; Amino Acids; beta-Thalassemia; Biomarkers; Bloo | 2001 |
[Laboratory diagnosis of osteoporosis].
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Child; | 2001 |
Biochemical markers of bone turnover.
Topics: Alkaline Phosphatase; Biomarkers; Bone Resorption; Humans; Hydroxylysine; Hydroxyproline; Osteocalci | 2001 |
Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies.
Topics: Chromatography, Gas; Chromatography, High Pressure Liquid; Dipeptides; Female; Humans; Hydroxyprolin | 2002 |
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
Topics: Adult; Aged; Bone Resorption; Diphosphonates; Female; Humans; Hydroxyproline; Male; Middle Aged; Mod | 2002 |
Treatment of osteoporosis of ageing with 1alpha-hydroxycholecalciferol.
Topics: Administration, Oral; Age Factors; Aged; Aging; Alkaline Phosphatase; Bone and Bones; Bone Regenerat | 1975 |
Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases.
Topics: Acromegaly; Adult; Alkaline Phosphatase; Bone Diseases; Bone Neoplasms; Female; Humans; Hydroxyproli | 1978 |
Bone metabolism, parathyroid hormone, and calcitonin in paraplegia.
Topics: Adolescent; Adult; Aged; Bone and Bones; Calcitonin; Calcium; Female; Humans; Hydroxyproline; Male; | 1979 |
Metabolic effects of corticosteroid therapy in post-menopausal women.
Topics: Androstenedione; Bone and Bones; Calcium; Creatinine; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1979 |
Bone and ageing.
Topics: Absorptiometry, Photon; Adolescent; Adult; Age Determination by Skeleton; Age Factors; Aged; Aging; | 1975 |
Effect of the diphosphonate EHDP on bone mineral metabolism during prolonged bed rest.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Depression, Chemical; Diphosp | 1975 |
Relationship between bone uptake of 99mTc-pyrophosphate and hydroxyproline in blood and urine.
Topics: Aged; Bone and Bones; Bone Diseases; Diphosphates; Female; Humans; Hydroxyproline; Hyperparathyroidi | 1976 |
The prevention and management of post-menopausal osteoporosis.
Topics: Aged; Bone and Bones; Calcium; Creatinine; Estradiol; Ethinyl Estradiol; Female; Humans; Hydroxyprol | 1977 |
Automated analysis of hydroxyproline with elimination of non-specific reacting substances.
Topics: Autoanalysis; Colorimetry; Humans; Hydroxyproline; Indicators and Reagents; Male; Osteitis Deformans | 1979 |
[Effects of the treatment of active osteoporosis on the urinary excretion of hydroxyproline].
Topics: Adult; Calcium Carbonate; Calcium Gluconate; Drug Therapy, Combination; Female; Humans; Hydroxyproli | 1979 |
Sitting, muscular exercises, and collagen metabolism in tetraplegia.
Topics: Adolescent; Adult; Bone Resorption; Calcium; Collagen; Humans; Hydroxyproline; Male; Osteoporosis; P | 1979 |
[Phospho-calcium metabolism in prolonged immobilization. Mechanism and consequences].
Topics: Bed Rest; Bone and Bones; Calcium; Humans; Hydroxyproline; Osteoporosis; Phosphorus; Physical Stimul | 1979 |
Combination therapy for osteoporosis.
Topics: Absorption; Aged; Animals; Bone and Bones; Calcitonin; Calcium; Drug Therapy, Combination; Female; G | 1977 |
[Recent acquisitions in therapy of osteoporosis of various etiologies with calcitonin].
Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Drug Evaluation; Electrolytes; Humans; Hy | 1977 |
The effect of 1alpha-hydroxyvitamin D3 with and without oestrogens on calcium balance in post-menopausal women.
Topics: Calcium; Drug Therapy, Combination; Estrogens; Female; Femoral Neck Fractures; Humans; Hydroxycholec | 1977 |
Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
Topics: Aged; Alkaline Phosphatase; Calcium; Female; Humans; Hydroxycholecalciferols; Hydroxyproline; Intest | 1978 |
Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women.
Topics: Adrenal Cortex Hormones; Androstenedione; Creatinine; Estrone; Female; Humans; Hydroxyproline; Menop | 1978 |
Actual concept of osteoporosis in paraplegia.
Topics: Amino Acids; Calcitonin; Calcium; Chemical Fractionation; Collagen; Female; Femur; Humans; Hydroxypr | 1978 |
[A test for acute hypocalcemia using swine and salmon calcitonin].
Topics: Acute Disease; Alkaline Phosphatase; Animals; Calcitonin; Calcium; Hydroxyproline; Hypocalcemia; Ost | 1977 |
Effect of 1alpha-hydroxycholecalciferol in senile osteoporosis and in bone loss following prednisone treatment.
Topics: Aged; Aging; Calcium; Humans; Hydroxycholecalciferols; Hydroxyproline; Osteoporosis; Prednisone | 1977 |
Effect of fluoride therapy on nondialyzable urinary hydroxyproline, serum alkaline phosphatase, parathyroid hormone, and 25-hydroxyvitamin D.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Calcium; Dialysis; Fluorides; Humans; Hydroxycholecalcif | 1977 |
[Urinary hydroxyproline in hyperthyroidism].
Topics: Adolescent; Adult; Aged; Diabetes Mellitus; Female; Humans; Hydroxyproline; Hyperthyroidism; Male; M | 1977 |
[Osteoporoses. Bone morphology and bone metabolism].
Topics: Adult; Alkaline Phosphatase; Calcium; Female; Humans; Hydroxyproline; Middle Aged; Osteoporosis | 1977 |
Effects of phosphorus supplementation on serum parathyroid hormone and bone morphology in osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Calcium, Dietary; Female; Huma | 1976 |
Relation to osteoporosis of age- and hormone-induced changes in the metabolism of collagen and bone.
Topics: Aging; Animals; Bone and Bones; Bone Matrix; Calcium; Collagen; Female; Hormones; Humans; Hydroxypro | 1976 |
Effects of growth hormone in osteoporosis.
Topics: Bone and Bones; Calcium; Female; Growth Hormone; Humans; Hydroxyproline; Male; Osteoporosis; Parathy | 1976 |
On an attempt to treat primary and secondary osteoporosis with human growth hormone.
Topics: Adult; Alkaline Phosphatase; Calcium; Follow-Up Studies; Growth Hormone; Humans; Hydroxyproline; Mal | 1975 |
Post-menopausal osteopenia and osteoporosis.
Topics: Adult; Bone and Bones; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; Male; M | 1975 |
[Biochemical markers of bone remodelling and their usefulness in the diagnosis of osteoporosis].
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Calcium; Creatinine; Female; Human | 1992 |
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.
Topics: Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Bone | 1992 |
Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics.
Topics: Absorptiometry, Photon; Adult; Alcoholism; Bone Density; Calcium; Creatinine; Fatty Acids, Nonesteri | 1992 |
Osteoporosis and Klinefelter's syndrome.
Topics: Adult; Aged; Body Composition; Bone Density; Creatinine; Dehydroepiandrosterone; Humans; Hydroxyprol | 1992 |
Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Bone D | 1992 |
Bone collagen, mineral and trace element composition, histomorphometry and urinary hydroxyproline excretion in chronically-treated alcohol-fed rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Bone and Bones; Bone Density; Collagen; DNA; Hydroxyproline; | 1991 |
[Prevalence of risk factors for osteoporosis and distribution of calciuria and hydroxyprolinuria in an elderly population of a general practice. Results of a survey among 32 practitioners of the Vaud and Fribourg districts].
Topics: Aged; Calcium; Calcium, Dietary; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteoporosis; Os | 1991 |
[Pathophysiology of osteoporosis and bone density determination].
Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcium; Estrogens; Female; Humans; Hydr | 1991 |
[Osteoporosis in thyroid disease].
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Humans; Hydroxyproline; Intestine, Small; Kidney; Ost | 1990 |
Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.
Topics: Animals; Body Weight; Bone and Bones; Bone Resorption; Buserelin; Calcium; Estradiol; Female; Femur; | 1990 |
Lower mobility and markers of bone resorption in the elderly.
Topics: Aged; Aged, 80 and over; Bone Resorption; Calcitriol; Calcium; Creatinine; Homes for the Aged; Human | 1990 |
[Increased risk of osteoporosis in thyroid hormone substitution therapy].
Topics: Aged; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteoporosis; Risk Factors; Thyroid Hormone | 1990 |
Calcitonin, estradiol, and hydroxyproline as parameters in the early diagnosis of involutional osteoporosis. The importance of the "second calcitonin phenomenon".
Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Estradiol; Female; Humans; Hydroxyproline; Mal | 1990 |
Biochemical predictors for osteoporotic fractures in elderly Chinese--a longitudinal study.
Topics: 25-Hydroxyvitamin D 2; Aged; Asian People; Biomarkers; Calcium; Cohort Studies; Creatinine; Data Col | 1990 |
Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects.
Topics: Adult; Alkaline Phosphatase; Asthma; Bone and Bones; Female; Humans; Hydroxyproline; Insulin-Like Gr | 1989 |
Age-related changes in organic and inorganic bone matrix constituents: the effect of environment and diet.
Topics: Aging; Animals; Bone and Bones; Calcium; Calcium-Binding Proteins; Energy Intake; Germ-Free Life; Hy | 1989 |
Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Topics: Aged; Alkaline Phosphatase; Calcium-Binding Proteins; Creatinine; Female; Humans; Hydroxyproline; Hy | 1989 |
Isotope retention for assessment of bone turnover in involutional osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Calcium-Binding Proteins; Huma | 1989 |
Bone involvement in primary hemochromatosis and alcoholic cirrhosis.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Density; Hemochromatosis; Humans; Hydroxyproline; Liver C | 1989 |
Effects of NaCl on calcium balance, parathyroid function and hydroxyproline excretion in prednisolone-treated rats consuming low calcium diet.
Topics: Absorption; Animals; Bone Resorption; Calcium; Cyclic AMP; Diet; Feces; Glucocorticoids; Hydroxyprol | 1986 |
Effect of estrogen (Premarin) replacement therapy on serum level of total estrogen and urinary excretion of calcium and hydroxyproline in postmenopausal Chinese women.
Topics: Adult; Aged; Bone and Bones; Calcium; Creatinine; Estrogens; Estrogens, Conjugated (USP); Female; Hu | 1986 |
Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women.
Topics: Aged; Calcitonin; Calcium; Female; Humans; Hydroxyproline; Middle Aged; Osteitis Deformans; Osteocla | 1986 |
Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Topics: Absorption; Aged; Bone and Bones; Calcium; Calcium Radioisotopes; Female; Humans; Hydroxyproline; Me | 1987 |
Hydroxyprolinuria in vibration disease.
Topics: Adult; Bone Cysts; Bone Diseases, Metabolic; Humans; Hydroxyproline; Middle Aged; Occupational Disea | 1988 |
Biochemical effects of calcium supplementation in postmenopausal osteoporosis.
Topics: Alkaline Phosphatase; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; Menopaus | 1988 |
Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
Topics: Aging; Biomarkers; Bone Resorption; Calcitonin; Calcium-Binding Proteins; Female; Humans; Hydroxypro | 1988 |
Increased in vitro bone resorption by monocytes in the hyper-immunoglobulin E syndrome.
Topics: Aspirin; Bone Resorption; Child; Child, Preschool; Dinoprostone; Female; Humans; Hydroxyproline; Hyp | 1988 |
99mTc-MDP retention in osteoporosis: relationship to other indices of bone cell activity and response to calcium and vitamin D therapy.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Calcium; Creatinine; Female; H | 1987 |
Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women.
Topics: Aged; Aged, 80 and over; Calcium; Creatinine; Female; Humans; Hydroxyproline; Menopause; Middle Aged | 1986 |
1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women.
Topics: Alkaline Phosphatase; Calcifediol; Calcitriol; Calcium; Calcium-Binding Proteins; Creatinine; Female | 1987 |
Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women.
Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Bone Resorption; Cross-Sectional Studies; Female; Hum | 1987 |
Evaluation of mineral metabolism and bone turnover in osteoporotic females treated with phosphorus and salmon calcitonin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Calcitonin; Cal | 1987 |
Bone turnover in spinal osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Development; Bone Resorption; Calcium; Calcium-Binding Prote | 1987 |
Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Calcitriol; Fractures, Spontaneous; Humans; Hydro | 1987 |
Urine glycosaminoglycans in a reference population: effects of age, body surface area, and postmenopausal status.
Topics: Adult; Aged; Aging; Body Constitution; Circadian Rhythm; Collagen; Female; Glycosaminoglycans; Human | 1987 |
Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis.
Topics: Aged; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; Kinetics; Middle Aged; O | 1987 |
[The role of the urinary hydroxyproline level in the screening for collagen diseases].
Topics: Adult; Aged; Arthritis, Rheumatoid; Collagen Diseases; Diabetes Mellitus; Female; Humans; Hydroxypro | 1986 |
Calcium supplements in the prevention of steroid-induced osteoporosis.
Topics: Adolescent; Adult; Aged; Bone and Bones; Calcium; Female; Humans; Hydroxyproline; Male; Middle Aged; | 1986 |
[Methods of study in the therapy of osteoporosis--clinical aspects, roentgenology, biochemistry].
Topics: Aged; Bone and Bones; Enzymes; Follow-Up Studies; Humans; Hydroxyproline; Middle Aged; Osteomalacia; | 1986 |
[Therapeutic choices in osteoporosis].
Topics: Aged; Aging; Bone and Bones; Bone Regeneration; Bone Resorption; Calcitonin; Calcium; Densitometry; | 1987 |
1,25-Dihydroxycalciferol and calcium therapy in osteoporosis with calcium malabsorption. Dose response relationship of calcium absorption and indices of bone turnover.
Topics: Alkaline Phosphatase; Bone Resorption; Calcitriol; Calcium; Creatinine; Dose-Response Relationship, | 1985 |
Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.
Topics: Adolescent; Calcitriol; Calcium; Diphosphonates; Humans; Hydroxyproline; Intestinal Absorption; Male | 1985 |
[Malignant primary osteoporosis. A special form in males in early and middle age].
Topics: Adult; Biopsy; Body Height; Bone and Bones; Calcifediol; Calcium; Follow-Up Studies; Fractures, Spon | 1985 |
Bone changes after castration in rats. A model for osteoporosis.
Topics: Animals; Body Weight; Bone and Bones; Calcitonin; Calcium; Female; Hydroxyproline; Male; Orchiectomy | 1986 |
[Long-term results of the treatment of postmenopausic osteoporosis with calcitonin and calcium].
Topics: Calcitonin; Calcium; Creatinine; Female; Follow-Up Studies; Humans; Hydroxyproline; Osteoporosis | 1985 |
The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women.
Topics: Aged; Alkaline Phosphatase; Bone Resorption; Calcium; Female; Humans; Hydroxyproline; Menopause; Mid | 1985 |
Clinical significance of free plasma hydroxyproline measurement in metabolic bone disease.
Topics: Adult; Aged; Amino Acids; Bone Diseases, Metabolic; Female; Humans; Hydroxyproline; Hyperparathyroid | 1985 |
Low serum magnesium concentration in Paget's disease of bone (osteitis deformans).
Topics: Absorption; Aged; Alkaline Phosphatase; Female; Humans; Hydroxyproline; Magnesium; Male; Middle Aged | 1985 |
Paget's bone disease: response to human calcitonin in patients resistant to salmon calcitonin.
Topics: Aged; Alkaline Phosphatase; Animals; Antibodies; Antibody Formation; Calcitonin; Calcium; Female; Hu | 1974 |
[Collagen metabolism in hyperthyroidism].
Topics: Adult; Alkaline Phosphatase; Biopsy; Bone and Bones; Calcium; Collagen; Female; Humans; Hydroxyproli | 1968 |
[Osseous localizations of mastocytosis].
Topics: Adult; Age Factors; Anemia; Bone Diseases; Bone Resorption; Calcium; Fluorides; Glucocorticoids; Hep | 1969 |
The glycosaminoglycans of compact bone tissue in experimental osteoporosis. Induced by combined oophorectomy and prednisolone treatment or prolonged calcium restriction in one year old rats.
Topics: Animals; Bone and Bones; Calcium; Castration; Deficiency Diseases; Female; Glycosaminoglycans; Hexos | 1968 |
The development of osteoporosis. Experimental studies in the adult rat.
Topics: Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Resorption; Calcium; Calcium Isotop | 1969 |
[The significance of the excretion of amino acids and acid mucopolysaccharides in the urine in orthopedic diseases].
Topics: Adolescent; Adult; Amino Acids; Bone Diseases; Chromatography, Paper; Collagen; Glycosaminoglycans; | 1969 |
Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Calcitonin; Calcium; Child, Presc | 1971 |
The reversibility of disuse osteoporosis. Experimental studies in the adult rat.
Topics: Animals; Bone and Bones; Bone Development; Calcium; Calcium Isotopes; Casts, Surgical; Densitometry; | 1972 |
[Osteoporosis and mastocytosis. Apropos of 2 cases].
Topics: Female; Humans; Hydroxyproline; Male; Middle Aged; Osteoporosis; Urticaria Pigmentosa | 1968 |
The urinary excretion of inorganic pyrophosphate in hyperparathyroidism, hyperthyroidism, Paget's disease and other disorders of bone metabolism.
Topics: Adolescent; Adult; Aged; Bone Diseases; Child; Child, Preschool; Diphosphates; Female; Humans; Hydro | 1969 |
Effect of estrogen on immobilization osteoporosis in rat.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Bone Resorption; Calcium; Casts, Surgical; Collagen | 1971 |
[Renal oxyproline, acid mucopolysaccharide and pyrophosphate elimination in senile osteoporosis and secondary forms of osteoporosis].
Topics: Adult; Aged; Diphosphates; Glycosaminoglycans; Humans; Hydroxyproline; Middle Aged; Osteoporosis | 1970 |
[Effect of hormones on bone metabolism].
Topics: Aged; Bone and Bones; Calcitonin; Diphosphates; Endocrine System Diseases; Glycosaminoglycans; Gonad | 1971 |
Phasic pattern of 17-ketosteroid- and hydroxyproline-excretion in urine of man after a single ACTH administration.
Topics: Adrenocorticotropic Hormone; Adult; Collagen; Diabetes Mellitus; Female; Humans; Hydroxyproline; Ket | 1969 |
[Osseous effects of hyperthyroidism].
Topics: Adolescent; Adult; Aged; Bone Diseases; Bone Resorption; Calcium; Calcium Metabolism Disorders; Fema | 1972 |
[Urinary hydroxyproline correlated with quantitative bone histological data. Attempted physiopathological interpretation].
Topics: Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Diseases; Bone Neoplasms; Bone Resorption; Humans | 1972 |
Laboratory aids in the diagnosis of metabolic bone disease.
Topics: Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Diseases; Calcium; Calcium, Dietary; Cyclic AMP; | 1972 |
Bone as a target organ: toward a better definition of osteoporosis.
Topics: Bone and Bones; Bone Matrix; Bone Resorption; Calcitonin; Calcium; Collagen; Cyclic AMP; Endocrine S | 1973 |
[Physiopathology of osteoporosis in the young adult].
Topics: Adult; Alkaline Phosphatase; Back Pain; Biopsy; Bone and Bones; Bone Resorption; Calcinosis; Calcium | 1974 |
Young adult osteoporosis.
Topics: Adult; Age Factors; Alkaline Phosphatase; Biological Transport; Bone and Bones; Bone Resorption; Cal | 1973 |
[Application of growth hormone in osteoporosis (author's transl)].
Topics: Adult; Alkaline Phosphatase; Calcium; Growth Hormone; Humans; Hydroxyproline; Injections, Intramuscu | 1974 |
Quantitative histological data on disuse osteoporosis: comparison with biological data.
Topics: Adipose Tissue; Adult; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Marrow; Bone Marrow Cells; | 1974 |
Use of porcine calcitonin in osteoporosis.
Topics: Animals; Calcitonin; Calcium; Feces; Female; Humans; Hydroxyproline; Magnesium; Male; Middle Aged; O | 1973 |
Corticosteroid osteoporosis.
Topics: Adult; Aged; Aging; Arthritis, Rheumatoid; Asthma; Autoanalysis; Bone and Bones; Calcium; Calcium Ra | 1973 |
Metabolic studies of bone in uremia before and after treatment.
Topics: Adult; Azathioprine; Bone and Bones; Bone Resorption; Carbon Isotopes; Chronic Kidney Disease-Minera | 1972 |
Chronic respiratory paralysis. A clinical study of 12 patients in long-term respirator treatment after poliomyelitis.
Topics: Adaptation, Physiological; Adolescent; Adult; Blood Pressure; Bone and Bones; Carbon Dioxide; Electr | 1972 |
Urinary total hydroxyproline, calcium and phosphorus excretion after administration of calcium and oestrogen to postmenopausal women.
Topics: Adult; Aged; Calcium; Climacteric; Estrogens; Female; Humans; Hydroxyproline; Middle Aged; Osteoporo | 1972 |
An evaluation of antibodies and clinical resistance to salmon calcitonin.
Topics: Adult; Aged; Animals; Antibodies; Antibody Formation; Autoradiography; Calcitonin; Calcium; Female; | 1972 |
Effect of acetylsalicyclic acid (aspirin) on bone collagen in children.
Topics: Aspirin; Bone and Bones; Child; Child, Preschool; Collagen; Growth Disorders; Humans; Hydroxyproline | 1973 |
Transient osteoporosis of the hip in pregnancy.
Topics: Adult; Bone and Bones; Bone Diseases; Calcium; Female; Femur Head; Femur Neck; Humans; Hydroxyprolin | 1973 |
Attempts to prevent disuse osteoporosis by treatment with calcitonin, longitudinal compression and supplementary calcium and phosphate.
Topics: Adult; Alkaline Phosphatase; Body Weight; Calcaneus; Calcitonin; Calcium; Humans; Hydroxyproline; Ma | 1973 |
Heparin osteoporosis. An experimental model using rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Collagen; Disease Models, Animal; Female; Fibrobla | 1973 |
[Treatment of osteoporosis by repeated calcium infusions].
Topics: Alkaline Phosphatase; Calcium; Humans; Hydroxyproline; Injections, Intravenous; Osteoporosis; Pain; | 1973 |
[Collagen metabolism in human osteoporosis].
Topics: Collagen; Female; Humans; Hydroxyproline; Male; Osteoporosis | 1973 |
[Metabolic effects of calcitonin in man].
Topics: Adult; Aged; Calcitonin; Calcium; Calcium Isotopes; Female; Humans; Hydroxyproline; Hypocalcemia; Ma | 1973 |
[Heparin-induced osteopathy in animal experiments--a model for osteoporosis? Influence of heparin on the concentrations of hydroxyapatite, citrate, and hydroxyproline in the bones of rats of various ages. I].
Topics: Animals; Bone and Bones; Citrates; Disease Models, Animal; Heparin; Hydroxyapatites; Hydroxyproline; | 1973 |
[Study of results obtained with thyrocalcitonin, in particular, with a radiodensitometric bone technic].
Topics: Absorptiometry, Photon; Aged; Calcitonin; Female; Humans; Hydroxyproline; Male; Methods; Middle Aged | 1973 |
[Biological exploration of osteoporosis (author's transl)].
Topics: Calcium; Glomerular Filtration Rate; Humans; Hydroxyproline; Osteoporosis; Phosphorus | 1973 |
UCLA conference: Current concepts of bone metabolism.
Topics: Animals; Bone and Bones; Bone Development; Bone Resorption; Calcitonin; Calcium; Calcium, Dietary; C | 1974 |
Osteoporosis in ovarian dysgenesis.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone Resorption; Calcium; Child; Female; Femur; Humans; Hyd | 1974 |
Letter: Calcitonin in steroid-induced osteoporosis.
Topics: Aged; Calcitonin; Calcium; Diet Therapy; Female; Humans; Hydroxyproline; Injections, Subcutaneous; L | 1974 |
Bone growth in protein deficiency. A study in rhesus monkeys.
Topics: Animals; Body Weight; Bone and Bones; Bone Development; Haplorhini; Hydroxyproline; Male; Osteoporos | 1968 |
Increased sensitivity of bone to parathyroid hormone in ovariectomized rats.
Topics: Animals; Body Weight; Calcium; Collagen; Estrogens; Female; Femur; Hydroxyproline; Osteoporosis; Ova | 1972 |
[Hydroxyprolinuria in skeletal diseases: its correlation with other parameters of bone metabolism].
Topics: Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bone Neoplasms; Calcium; Humans; Hydroxyproline | 1972 |
Hydroxyproline and transient osteoporosis.
Topics: Female; Humans; Hydroxyproline; Osteoporosis; Pregnancy; Pregnancy Complications | 1972 |
Treatment of osteoporosis with calcium infusions.
Topics: Bone Resorption; Calcitonin; Calcium; Humans; Hydroxyproline; Infusions, Parenteral; Osteoporosis; P | 1972 |
Juvenile osteoporosis: bone findings in seven patients.
Topics: Adolescent; Alkaline Phosphatase; Bone Regeneration; Bone Resorption; Calcium; Female; Fractures, Sp | 1972 |
Osteoporosis in aging rats induced by high phosphorus diets.
Topics: Aging; Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone and Bones; Bone Resorp | 1972 |
The solubility and synthetic rate of bone collagen in idiopathic osteoporosis.
Topics: Adolescent; Adult; Aging; Bone and Bones; Bone Matrix; Carbon Isotopes; Climacteric; Collagen; DNA; | 1972 |
Radiological osteoporosis: correlation with dietary and biochemical findings.
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Calcium; Calcium, Dietary; Creatinine; Dietary Pro | 1971 |
Plasma kinetics and acute effects of pharmacologic doses of porcine calcitonin in man.
Topics: Adult; Aged; Animals; Calcitonin; Calcium; Chromatography, Ion Exchange; Circadian Rhythm; Computers | 1971 |
[The role of thyrocalcitonin in age induced osteoporosis].
Topics: Age Factors; Aged; Animals; Calcitonin; Calcium; Gonadal Steroid Hormones; Humans; Hydroxyproline; M | 1971 |
Clinical significance of urinary and serum hydroxyproline determination in sarcoidosis.
Topics: Adult; Aged; Alkaline Phosphatase; Calcium; Female; Foot; Hand; Humans; Hydroxyproline; Male; Middle | 1971 |
The effect of supplemental oral phosphate on the bone mineral changes during prolonged bed rest.
Topics: Administration, Oral; Adult; Alkaline Phosphatase; Body Weight; Bone and Bones; Bone Resorption; Cal | 1971 |
[Immobilization-induced hypercalcemia. A review together with 1 personal case].
Topics: Adolescent; Adrenal Cortex Hormones; Blood Pressure; Calcium; Calcium Sulfate; Creatinine; Femur; Fr | 1971 |
Metabolic studies and 47 Ca kinetics during high calcium intake in senile osteoporosis.
Topics: Aged; Aging; Bone Resorption; Calcium; Calcium Isotopes; Female; Humans; Hydroxyproline; Kinetics; M | 1971 |
[Problems of modern physiopathology of phospho-calcium metabolism].
Topics: Calcium; Calcium Isotopes; Female; Humans; Hydroxyproline; Intestinal Absorption; Intestinal Mucosa; | 1971 |
[Correlation of hydroxyprolinuria and other parameters of bone metabolism].
Topics: Bone and Bones; Bone Diseases; Bone Neoplasms; Collagen; Humans; Hydroxyproline; Osteoporosis | 1970 |
[Metabolic rates and histological-morphometrical investigations in bones of patients wtth osteoporosis subjected to long-term application of calcitonin].
Topics: Adult; Age Factors; Biopsy; Bone and Bones; Calcitonin; Calcium; Female; Humans; Hydroxyproline; Mag | 1971 |
[Study of urinary hydroxyproline in osteopathies].
Topics: Acromegaly; Adult; Aged; Bone Neoplasms; Female; Humans; Hydroxyproline; Hyperparathyroidism; Hypert | 1966 |
The acute effects of porcine calcitonin in man.
Topics: Adult; Aged; Animals; Bone Resorption; Calcitonin; Calcium; Creatinine; Female; Humans; Hydroxyproli | 1969 |
[An anabolic agent of the androstane-pyrazole type and the evaluation of anabolic treatment].
Topics: Arthritis, Rheumatoid; Calcium; Chemical Phenomena; Chemistry; Female; Humans; Hydroxyproline; Male; | 1969 |
[Long-term treatment with thyrocalcitonin in senile osteoporosis: metabolic aspects].
Topics: Aged; Calcitonin; Calcium; Female; Humans; Hydroxyproline; Middle Aged; Osteoporosis; Phosphates | 1970 |
Calcium metabolism and 47calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Calcium Isotopes; Creatinine; Feces | 1970 |
Treatment of osteoporosis by calcium infusions.
Topics: Bone and Bones; Bone Resorption; Calcitonin; Calcium; Humans; Hydroxyproline; Microradiography; Oste | 1970 |
[Osteopathy in diabetes. Clinical and pathogenic study].
Topics: Adult; Age Factors; Aged; Arthropathy, Neurogenic; Calcium; Diabetes Complications; Diabetes Mellitu | 1970 |
Treatment of osteoporosis with calcium infusions.
Topics: Absorption; Adult; Aged; Bone and Bones; Calcitonin; Calcium; Calcium Isotopes; Female; Humans; Hydr | 1970 |
[Treatment of atrophic osteopathies with sodium fluoride].
Topics: Aged; Alkaline Phosphatase; Analgesia; Atrophy; Biopsy; Bone and Bones; Calcium; Female; Fluorides; | 1970 |
An epidemiological study of osteoporosis in Israel.
Topics: Adult; Age Factors; Aged; Calcium; Diet; Dietary Proteins; Epidemiology; Ethnicity; Feeding Behavior | 1971 |
[Biological monitoring during treatments of systemic osteoporosis. Therapeutic deductions].
Topics: Aged; Anabolic Agents; Calcium; Estrogens; Female; Humans; Hydroxyproline; Magnesium; Male; Osteopor | 1971 |
Clinical applications of calcitonin.
Topics: Alkaline Phosphatase; Calcitonin; Calcium; Humans; Hydroxyproline; Injections, Intramuscular; Osteit | 1971 |
Aortic calcification in Israel. An epidemiological study.
Topics: Adult; Africa, Northern; Age Factors; Aged; Aortic Diseases; Asia; Calcinosis; Calcium; Emigration a | 1971 |
[Collagen metabolism and corticosteroids].
Topics: Age Factors; Animals; Bone and Bones; Collagen; Collagen Diseases; Hydroxyproline; Methylprednisolon | 1967 |
[Urinary hydroxyproline excretion in generalized bone diseases].
Topics: Adult; Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Diseases; Bone Neoplasms; Female; Hum | 1967 |
Some effects of ethinyl oestradiol on calcium and phosphorus metabolism in osteoporosis.
Topics: Adult; Aged; Bone Resorption; Calcium; Ethinyl Estradiol; Feces; Female; Humans; Hydroxyproline; Men | 1968 |
Hyperprolinemia and hyperprolinuria in thalassemia.
Topics: Adolescent; Child; Child, Preschool; Humans; Hydroxyproline; Osteoporosis; Proline; Thalassemia | 1968 |
Effect of disuse osteoporosis on bone composition: the fate of bone matrix.
Topics: Animals; Atrophy; Bone and Bones; Bone Resorption; Collagen; Dogs; Femur; Humerus; Hydroxyproline; M | 1968 |
[On diagnosis and treatment of osteoporosis].
Topics: Adult; Age Factors; Aged; Calcium; Calcium, Dietary; Diagnosis, Differential; Humans; Hydroxyproline | 1968 |
Effect of sex hormones on bone in primary osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Estrogens; Female; Huma | 1969 |
Bone matrix turnover and balance in vitro. II. The effects of aging.
Topics: Aging; Animals; Bone and Bones; Bone Resorption; Collagen; DNA; Hydroxyproline; In Vitro Techniques; | 1969 |
[Correlation between hydroxyprolinuria, alkaline phosphatasemia and Ca45 dynamics].
Topics: Adult; Aged; Alkaline Phosphatase; Bone Resorption; Calcium; Female; Humans; Hydroxyproline; Hyperpa | 1965 |
Primary hyperparathyroidism--evaluation of diagnostic aids: calcium infusion, phosphorus deprivation and hydroxyprolinuria.
Topics: Calcium; Diet; Humans; Hydroxyproline; Hyperparathyroidism; Kidney Calculi; Osteoporosis; Phosphates | 1966 |
[The excretion of hydroxyproline and proline peptide in osteomalacia and osteoporosis].
Topics: Adult; Aged; Chromatography, Paper; Collagen; Colorimetry; Female; Humans; Hydroxyproline; Male; Mid | 1966 |
[Diagnosis of primary hyperparathyroidism].
Topics: Diagnosis, Differential; Humans; Hydroxyproline; Hyperparathyroidism; Osteomalacia; Osteoporosis; Pr | 1966 |
[On the excretion of bound hydroxyproline as an expression of changes in the organic cartilage and bone matrix].
Topics: Adolescent; Bone and Bones; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cartilage; Ehlers-Danlo | 1966 |
[Metabolism of collagen and hydroxprolinuria in thyroid diseases].
Topics: Adult; Alkaline Phosphatase; Calcium; Collagen; Female; Humans; Hydroxyproline; Hyperthyroidism; Hyp | 1966 |